|
EP2449112A1
(en)
|
2009-07-01 |
2012-05-09 |
Transposagen Biopharmaceuticals, Inc. |
Genetically modified rat models for severe combined immunodeficiency (scid)
|
|
MX2013010911A
(es)
|
2011-03-23 |
2015-03-03 |
Pioneer Hi Bred Int |
Metodos para producir un locus de rasgo transgenico complejo.
|
|
JP6261500B2
(ja)
|
2011-07-22 |
2018-01-17 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ヌクレアーゼ切断特異性の評価および改善
|
|
GB201117313D0
(en)
|
2011-10-07 |
2011-11-16 |
Gt Biolog Ltd |
Bacterium for use in medicine
|
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
|
US10039777B2
(en)
|
2012-03-20 |
2018-08-07 |
Neuro-Lm Sas |
Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
|
|
IN2014DN09261A
(https=)
|
2012-04-25 |
2015-07-10 |
Regeneron Pharma |
|
|
EP3241902B1
(en)
|
2012-05-25 |
2018-02-28 |
The Regents of The University of California |
Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
|
|
US10648001B2
(en)
|
2012-07-11 |
2020-05-12 |
Sangamo Therapeutics, Inc. |
Method of treating mucopolysaccharidosis type I or II
|
|
DK3444342T3
(da)
|
2012-07-11 |
2020-08-24 |
Sangamo Therapeutics Inc |
Fremgangsmåder og sammensætninger til behandlingen af lysosomale aflejringssygdomme
|
|
KR102530118B1
(ko)
*
|
2012-07-25 |
2023-05-08 |
더 브로드 인스티튜트, 인코퍼레이티드 |
유도 ｄｎａ 결합 단백질 및 게놈 교란 도구 및 이의 적용
|
|
EP4357457B1
(en)
|
2012-10-23 |
2024-10-16 |
Toolgen Incorporated |
Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
|
|
EP3363902B1
(en)
|
2012-12-06 |
2019-11-27 |
Sigma Aldrich Co. LLC |
Crispr-based genome modification and regulation
|
|
WO2014093718A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
DK2931898T3
(en)
|
2012-12-12 |
2016-06-20 |
Massachusetts Inst Technology |
CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
|
|
AU2013359262C1
(en)
|
2012-12-12 |
2021-05-13 |
Massachusetts Institute Of Technology |
CRISPR-Cas component systems, methods and compositions for sequence manipulation
|
|
DK2931897T3
(en)
|
2012-12-12 |
2018-02-05 |
Broad Inst Inc |
CONSTRUCTION, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTICAL APPLICATIONS
|
|
EP2931899A1
(en)
|
2012-12-12 |
2015-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
|
WO2014093709A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
CA2894684A1
(en)
*
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes
|
|
CA2895155C
(en)
|
2012-12-17 |
2021-07-06 |
President And Fellows Of Harvard College |
Rna-guided human genome engineering
|
|
EP3919505B1
(en)
|
2013-01-16 |
2023-08-30 |
Emory University |
Uses of cas9-nucleic acid complexes
|
|
MX2015010841A
(es)
|
2013-02-20 |
2016-05-09 |
Regeneron Pharma |
Modificacion genetica de ratas.
|
|
MX374090B
(es)
|
2013-03-14 |
2025-03-05 |
Caribou Biosciences Inc |
Composiciones y métodos de ácidos nucleicos dirigidos al ácido nucleico.
|
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
|
WO2014204578A1
(en)
|
2013-06-21 |
2014-12-24 |
The General Hospital Corporation |
Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
|
|
AU2014227653B2
(en)
|
2013-03-15 |
2017-04-20 |
The General Hospital Corporation |
Using RNA-guided foki nucleases (RFNs) to increase specificity for RNA-guided genome editing
|
|
US9234213B2
(en)
|
2013-03-15 |
2016-01-12 |
System Biosciences, Llc |
Compositions and methods directed to CRISPR/Cas genomic engineering systems
|
|
JP2016522679A
(ja)
|
2013-04-04 |
2016-08-04 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ＣＲＩＳＰＲ／Ｃａｓ系を用いたゲノム編集の治療的使用
|
|
GB201306536D0
(en)
|
2013-04-10 |
2013-05-22 |
Gt Biolog Ltd |
Polypeptide and immune modulation
|
|
US20160186208A1
(en)
*
|
2013-04-16 |
2016-06-30 |
Whitehead Institute For Biomedical Research |
Methods of Mutating, Modifying or Modulating Nucleic Acid in a Cell or Nonhuman Mammal
|
|
SI2986729T1
(sl)
|
2013-04-16 |
2019-02-28 |
Regeneron Pharmaceuticals, Inc. |
Ciljana sprememba genoma podgane
|
|
WO2014186686A2
(en)
*
|
2013-05-17 |
2014-11-20 |
Two Blades Foundation |
Targeted mutagenesis and genome engineering in plants using rna-guided cas nucleases
|
|
US11685935B2
(en)
*
|
2013-05-29 |
2023-06-27 |
Cellectis |
Compact scaffold of Cas9 in the type II CRISPR system
|
|
WO2014194190A1
(en)
*
|
2013-05-30 |
2014-12-04 |
The Penn State Research Foundation |
Gene targeting and genetic modification of plants via rna-guided genome editing
|
|
WO2014204724A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
|
|
MX2015017312A
(es)
|
2013-06-17 |
2017-04-10 |
Broad Inst Inc |
Suministro y uso de composiciones, vectores y sistemas crispr-cas para la modificación dirigida y terapia hepáticas.
|
|
EP3725885A1
(en)
|
2013-06-17 |
2020-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
|
KR20250012194A
(ko)
|
2013-06-17 |
2025-01-23 |
더 브로드 인스티튜트, 인코퍼레이티드 |
바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
|
|
EP3011030B1
(en)
|
2013-06-17 |
2023-11-08 |
The Broad Institute, Inc. |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
|
JP2016528890A
(ja)
|
2013-07-09 |
2016-09-23 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ＣＲＩＳＰＲ／Ｃａｓ系を用いるゲノム編集の治療用の使用
|
|
WO2015006294A2
(en)
*
|
2013-07-10 |
2015-01-15 |
President And Fellows Of Harvard College |
Orthogonal cas9 proteins for rna-guided gene regulation and editing
|
|
US10563225B2
(en)
*
|
2013-07-26 |
2020-02-18 |
President And Fellows Of Harvard College |
Genome engineering
|
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
CA3109801C
(en)
*
|
2013-08-22 |
2024-01-09 |
Andrew Cigan |
Plant genome modification using guide rna/cas endonuclease systems and methods of use
|
|
US9925248B2
(en)
|
2013-08-29 |
2018-03-27 |
Temple University Of The Commonwealth System Of Higher Education |
Methods and compositions for RNA-guided treatment of HIV infection
|
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
|
EP3418379B1
(en)
|
2013-09-18 |
2020-12-09 |
Kymab Limited |
Methods, cells & organisms
|
|
WO2015054507A1
(en)
|
2013-10-10 |
2015-04-16 |
Pronutria, Inc. |
Nutritive polypeptide production systems, and methods of manufacture and use thereof
|
|
WO2015065964A1
(en)
|
2013-10-28 |
2015-05-07 |
The Broad Institute Inc. |
Functional genomics using crispr-cas systems, compositions, methods, screens and applications thereof
|
|
AU2014346559B2
(en)
|
2013-11-07 |
2020-07-09 |
Editas Medicine,Inc. |
CRISPR-related methods and compositions with governing gRNAs
|
|
EP3760719A1
(en)
*
|
2013-11-18 |
2021-01-06 |
CRISPR Therapeutics AG |
Crispr-cas system materials and methods
|
|
US9074199B1
(en)
|
2013-11-19 |
2015-07-07 |
President And Fellows Of Harvard College |
Mutant Cas9 proteins
|
|
US9546384B2
(en)
|
2013-12-11 |
2017-01-17 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for the targeted modification of a mouse genome
|
|
EP3470089A1
(en)
|
2013-12-12 |
2019-04-17 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
|
|
AU2014361834B2
(en)
|
2013-12-12 |
2020-10-22 |
Massachusetts Institute Of Technology |
CRISPR-Cas systems and methods for altering expression of gene products, structural information and inducible modular Cas enzymes
|
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
|
MX2016007325A
(es)
|
2013-12-12 |
2017-07-19 |
Broad Inst Inc |
Composiciones y metodos de uso de sistemas crispr-cas en desordenes debidos a repeticion de nucleotidos.
|
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
|
EP3080259B1
(en)
|
2013-12-12 |
2023-02-01 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
BR112016013207A2
(pt)
|
2013-12-12 |
2017-09-26 |
Massachusetts Inst Technology |
administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para o hbv e distúrbios e doenças virais
|
|
JP6793547B2
(ja)
|
2013-12-12 |
2020-12-02 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
|
|
AU2014361781B2
(en)
*
|
2013-12-12 |
2021-04-01 |
Massachusetts Institute Of Technology |
Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing
|
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
|
EP4063503A1
(en)
|
2014-02-11 |
2022-09-28 |
The Regents of the University of Colorado, a body corporate |
Crispr enabled multiplexed genome engineering
|
|
JP2017506893A
(ja)
*
|
2014-02-18 |
2017-03-16 |
デューク ユニバーシティ |
ウイルス複製不活化組成物並びにその製造方法及び使用
|
|
EP3110971B1
(en)
|
2014-02-27 |
2019-05-08 |
The Broad Institute Inc. |
T cell balance gene expression and methods of use thereof
|
|
US11186843B2
(en)
|
2014-02-27 |
2021-11-30 |
Monsanto Technology Llc |
Compositions and methods for site directed genomic modification
|
|
WO2015134812A1
(en)
|
2014-03-05 |
2015-09-11 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
|
|
US11339437B2
(en)
|
2014-03-10 |
2022-05-24 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
|
US11141493B2
(en)
|
2014-03-10 |
2021-10-12 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
|
WO2015138510A1
(en)
|
2014-03-10 |
2015-09-17 |
Editas Medicine., Inc. |
Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
|
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
|
US11242525B2
(en)
|
2014-03-26 |
2022-02-08 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for treating sickle cell disease
|
|
WO2015153789A1
(en)
*
|
2014-04-01 |
2015-10-08 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating herpes simplex virus type 1 (hsv-1)
|
|
US12460231B2
(en)
|
2014-04-02 |
2025-11-04 |
Editas Medicine, Inc. |
Crispr/CAS-related methods and compositions for treating primary open angle glaucoma
|
|
AU2015244039B2
(en)
|
2014-04-07 |
2021-10-21 |
Novartis Ag |
Treatment of cancer using anti-CD19 chimeric antigen receptor
|
|
EP3556858A3
(en)
|
2014-04-09 |
2020-01-22 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating cystic fibrosis
|
|
CA2945335A1
(en)
*
|
2014-04-18 |
2015-10-22 |
Editas Medicine, Inc. |
Crispr-cas-related methods, compositions and components for cancer immunotherapy
|
|
EP3149171A1
(en)
|
2014-05-30 |
2017-04-05 |
The Board of Trustees of The Leland Stanford Junior University |
Compositions and methods of delivering treatments for latent viral infections
|
|
RS60359B1
(sr)
|
2014-06-06 |
2020-07-31 |
Regeneron Pharma |
Postupci i kompozicije za modifikovanje ciljanog lokusa
|
|
US11491480B2
(en)
|
2014-06-13 |
2022-11-08 |
Children's Medical Center Corporation |
Products and methods to isolate mitochondria
|
|
EP3919621A1
(en)
|
2014-06-23 |
2021-12-08 |
The General Hospital Corporation |
Genomewide unbiased identification of dsbs evaluated by sequencing (guide-seq)
|
|
KR102386101B1
(ko)
|
2014-06-26 |
2022-04-14 |
리제너론 파마슈티칼스 인코포레이티드 |
표적화된 유전자 변형을 위한 방법 및 그 조성물, 및 사용 방법
|
|
AU2015288157A1
(en)
|
2014-07-11 |
2017-01-19 |
E. I. Du Pont De Nemours And Company |
Compositions and methods for producing plants resistant to glyphosate herbicide
|
|
EP3169778B1
(en)
*
|
2014-07-14 |
2023-10-25 |
Washington State University |
Nanos knock-out that ablates germline cells
|
|
CN104152414B
(zh)
*
|
2014-07-18 |
2018-03-13 |
中国科学院广州生物医药与健康研究院 |
对细胞基因组的预定位点进行基因改造的方法
|
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
TWI750110B
(zh)
|
2014-07-21 |
2021-12-21 |
瑞士商諾華公司 |
使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
WO2016022363A2
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
ES2781175T3
(es)
|
2014-07-31 |
2020-08-31 |
Novartis Ag |
Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
|
|
CN106922154B
(zh)
*
|
2014-08-06 |
2022-01-07 |
基因工具股份有限公司 |
使用空肠弯曲杆菌crispr/cas系统衍生的rna引导的工程化核酸酶的基因编辑
|
|
WO2016025469A1
(en)
*
|
2014-08-11 |
2016-02-18 |
The Board Of Regents Of The University Of Texas System |
Prevention of muscular dystrophy by crispr/cas9-mediated gene editing
|
|
CA2958200A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
|
|
EP3686279B1
(en)
|
2014-08-17 |
2023-01-04 |
The Broad Institute, Inc. |
Genome editing using cas9 nickases
|
|
ES2791248T3
(es)
|
2014-08-19 |
2020-11-03 |
Novartis Ag |
Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
|
|
ES2730378T3
(es)
|
2014-08-27 |
2019-11-11 |
Caribou Biosciences Inc |
Procedimientos para incrementar la eficiencia de la modificación mediada por Cas9
|
|
WO2016036754A1
(en)
|
2014-09-02 |
2016-03-10 |
The Regents Of The University Of California |
Methods and compositions for rna-directed target dna modification
|
|
CN108064129A
(zh)
|
2014-09-12 |
2018-05-22 |
纳幕尔杜邦公司 |
玉米和大豆中复合性状基因座的位点特异性整合位点的产生和使用方法
|
|
KR20250067191A
(ko)
|
2014-09-17 |
2025-05-14 |
노파르티스 아게 |
입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
|
|
WO2016049163A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
|
|
WO2016049024A2
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling competition of multiple cancer mutations in vivo
|
|
WO2016049251A1
(en)
|
2014-09-24 |
2016-03-31 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of the crispr-cas systems and compositions for modeling mutations in leukocytes
|
|
US10040048B1
(en)
|
2014-09-25 |
2018-08-07 |
Synthego Corporation |
Automated modular system and method for production of biopolymers
|
|
WO2016049258A2
(en)
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
|
US20160090603A1
(en)
*
|
2014-09-30 |
2016-03-31 |
Sandia Corporation |
Delivery platforms for the domestication of algae and plants
|
|
CN104546931B
(zh)
*
|
2014-09-30 |
2019-04-09 |
深圳华大基因科技有限公司 |
华德萨特氏菌在治疗或预防类风湿性关节炎或其相关疾病中的应用
|
|
US10583201B2
(en)
*
|
2014-10-10 |
2020-03-10 |
Massachusetts Eye And Ear Infirmary |
Efficient delivery of therapeutic molecules in vitro and in vivo
|
|
EP3204496A1
(en)
|
2014-10-10 |
2017-08-16 |
Editas Medicine, Inc. |
Compositions and methods for promoting homology directed repair
|
|
GB201418965D0
(https=)
|
2014-10-24 |
2014-12-10 |
Ospedale San Raffaele And Fond Telethon |
|
|
WO2016069591A2
(en)
|
2014-10-27 |
2016-05-06 |
The Broad Institute Inc. |
Compositions, methods and use of synthetic lethal screening
|
|
WO2016073955A2
(en)
|
2014-11-06 |
2016-05-12 |
President And Fellows Of Harvard College |
Cells lacking b2m surface expression and methods for allogeneic administration of such cells
|
|
CA2963820A1
(en)
|
2014-11-07 |
2016-05-12 |
Editas Medicine, Inc. |
Methods for improving crispr/cas-mediated genome-editing
|
|
US10858662B2
(en)
|
2014-11-19 |
2020-12-08 |
Institute For Basic Science |
Genome editing with split Cas9 expressed from two vectors
|
|
EP3222718A4
(en)
*
|
2014-11-20 |
2018-05-30 |
Kyoto University |
Method for knock-in of dna into target region of mammalian genome, and cell
|
|
ES2731437T3
(es)
|
2014-11-21 |
2019-11-15 |
Regeneron Pharma |
Métodos y composiciones para la modificación genética dirigida mediante el uso de pares de ARN guías
|
|
EP3224381B1
(en)
|
2014-11-25 |
2019-09-04 |
The Brigham and Women's Hospital, Inc. |
Method of identifying a person having a predisposition to or afflicted with a cardiometabolic disease
|
|
CA2969145A1
(en)
|
2014-11-26 |
2016-06-02 |
The Regents Of The University Of California |
Therapeutic compositions comprising transcription factors and methods of making and using the same
|
|
GB201421096D0
(en)
|
2014-11-27 |
2015-01-14 |
Imp Innovations Ltd |
Genome editing methods
|
|
US10900034B2
(en)
|
2014-12-03 |
2021-01-26 |
Agilent Technologies, Inc. |
Guide RNA with chemical modifications
|
|
AU2015360502A1
(en)
|
2014-12-10 |
2017-06-29 |
Regents Of The University Of Minnesota |
Genetically modified cells, tissues, and organs for treating disease
|
|
EP3889260A1
(en)
|
2014-12-12 |
2021-10-06 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
|
WO2016094880A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
|
|
WO2016094872A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Dead guides for crispr transcription factors
|
|
CN112877327B
(zh)
*
|
2014-12-18 |
2024-11-22 |
综合基因技术公司 |
基于crispr的组合物和使用方法
|
|
US20190054117A1
(en)
|
2014-12-19 |
2019-02-21 |
Novartis Ag |
Dimerization switches and uses thereof
|
|
KR102530821B1
(ko)
|
2014-12-19 |
2023-05-10 |
리제너론 파마슈티칼스 인코포레이티드 |
단일 단계 다중 표적화를 통한 표적화된 유전자 변형을 위한 방법 및 조성물
|
|
EP3234192B1
(en)
|
2014-12-19 |
2021-07-14 |
The Broad Institute, Inc. |
Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
|
|
SG11201704814SA
(en)
|
2014-12-23 |
2017-07-28 |
4D Pharma Res Ltd |
Pirin polypeptide and immune modulation
|
|
WO2016102950A1
(en)
|
2014-12-23 |
2016-06-30 |
4D Pharma Research Limited |
Immune modulation
|
|
CA2969151A1
(en)
|
2014-12-23 |
2016-06-30 |
Syngenta Participations Ag |
Methods and compositions for identifying and enriching for cells comprising site specific genomic modifications
|
|
WO2016106236A1
(en)
|
2014-12-23 |
2016-06-30 |
The Broad Institute Inc. |
Rna-targeting system
|
|
WO2016106244A1
(en)
|
2014-12-24 |
2016-06-30 |
The Broad Institute Inc. |
Crispr having or associated with destabilization domains
|
|
WO2016108926A1
(en)
|
2014-12-30 |
2016-07-07 |
The Broad Institute Inc. |
Crispr mediated in vivo modeling and genetic screening of tumor growth and metastasis
|
|
WO2016114972A1
(en)
|
2015-01-12 |
2016-07-21 |
The Regents Of The University Of California |
Heterodimeric cas9 and methods of use thereof
|
|
WO2016123243A1
(en)
|
2015-01-28 |
2016-08-04 |
The Regents Of The University Of California |
Methods and compositions for labeling a single-stranded target nucleic acid
|
|
EP3250691B9
(en)
|
2015-01-28 |
2023-08-02 |
Caribou Biosciences, Inc. |
Crispr hybrid dna/rna polynucleotides and methods of use
|
|
EP3262162A4
(en)
*
|
2015-02-23 |
2018-08-08 |
Voyager Therapeutics, Inc. |
Regulatable expression using adeno-associated virus (aav)
|
|
EP3262193A2
(en)
|
2015-02-26 |
2018-01-03 |
The Broad Institute Inc. |
T cell balance gene expression, compositions of matters and methods of use thereof
|
|
JP6871169B2
(ja)
|
2015-03-02 |
2021-05-12 |
シナイ ヘルス システム |
相同組換え因子
|
|
EP3265559B1
(en)
|
2015-03-03 |
2021-01-06 |
The General Hospital Corporation |
Engineered crispr-cas9 nucleases with altered pam specificity
|
|
BR112017017260A2
(pt)
|
2015-03-27 |
2018-04-17 |
Du Pont |
construções de dna, vetor, célula, plantas, semente, método de expressão de rna e método de modificação de local alvo
|
|
EP3748004A1
(en)
*
|
2015-04-01 |
2020-12-09 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating duchenne muscular dystrophy and becker muscular dystrophy
|
|
EP3280803B1
(en)
*
|
2015-04-06 |
2021-05-26 |
The Board of Trustees of the Leland Stanford Junior University |
Chemically modified guide rnas for crispr/cas-mediated gene regulation
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
CA2982966C
(en)
|
2015-04-24 |
2024-02-20 |
Editas Medicine, Inc. |
Evaluation of cas9 molecule/guide rna molecule complexes
|
|
WO2016182893A1
(en)
|
2015-05-08 |
2016-11-17 |
Teh Broad Institute Inc. |
Functional genomics using crispr-cas systems for saturating mutagenesis of non-coding elements, compositions, methods, libraries and applications thereof
|
|
EP3294342A4
(en)
|
2015-05-08 |
2018-11-07 |
President and Fellows of Harvard College |
Universal donor stem cells and related methods
|
|
AU2016261358B2
(en)
|
2015-05-11 |
2021-09-16 |
Editas Medicine, Inc. |
Optimized CRISPR/Cas9 systems and methods for gene editing in stem cells
|
|
WO2016183438A1
(en)
*
|
2015-05-14 |
2016-11-17 |
Massachusetts Institute Of Technology |
Self-targeting genome editing system
|
|
CN107849546A
(zh)
*
|
2015-05-15 |
2018-03-27 |
先锋国际良种公司 |
对cas内切核酸酶系统、pam序列和指导rna元件的快速表征
|
|
EP3331582A4
(en)
*
|
2015-05-29 |
2019-08-07 |
Agenovir Corporation |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF TRANSPLANTATION CELLS
|
|
US10117911B2
(en)
|
2015-05-29 |
2018-11-06 |
Agenovir Corporation |
Compositions and methods to treat herpes simplex virus infections
|
|
EA037359B1
(ru)
|
2015-06-01 |
2021-03-17 |
Тэмпл Юниверсити - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн |
Способы и композиции для рнк-направляемого лечения инфекции, вызываемой вич
|
|
EP3303634B1
(en)
|
2015-06-03 |
2023-08-30 |
The Regents of The University of California |
Cas9 variants and methods of use thereof
|
|
WO2016196887A1
(en)
|
2015-06-03 |
2016-12-08 |
Board Of Regents Of The University Of Nebraska |
Dna editing using single-stranded dna
|
|
EP3302525A2
(en)
|
2015-06-05 |
2018-04-11 |
Novartis AG |
Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
|
|
EP3307887A1
(en)
|
2015-06-09 |
2018-04-18 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for improving transplantation
|
|
MA41010B1
(fr)
|
2015-06-15 |
2020-01-31 |
4D Pharma Res Ltd |
Compositions comprenant des souches bactériennes
|
|
HRP20191949T1
(hr)
|
2015-06-15 |
2020-01-24 |
4D Pharma Research Limited |
Blautia stercosis i wexlerae za upotrebu u liječenju upalnih i autoimunih bolesti
|
|
WO2016203221A1
(en)
|
2015-06-15 |
2016-12-22 |
4D Pharma Research Limited |
Compositions comprising bacterial strains
|
|
KR102468240B1
(ko)
|
2015-06-15 |
2022-11-17 |
노쓰 캐롤라이나 스테이트 유니버시티 |
핵산 및 rna-기반 항미생물제를 효율적으로 전달하기 위한 방법 및 조성물
|
|
ME03511B
(me)
|
2015-06-15 |
2020-04-20 |
4D Pharma Res Ltd |
Kompozicije koje sadrže bakterijske sojeve
|
|
MA41060B1
(fr)
|
2015-06-15 |
2019-11-29 |
4D Pharma Res Ltd |
Compositions comprenant des souches bactériennes
|
|
US11643668B2
(en)
|
2015-06-17 |
2023-05-09 |
The Uab Research Foundation |
CRISPR/Cas9 complex for genomic editing
|
|
WO2016205728A1
(en)
|
2015-06-17 |
2016-12-22 |
Massachusetts Institute Of Technology |
Crispr mediated recording of cellular events
|
|
CA2989858A1
(en)
|
2015-06-17 |
2016-12-22 |
The Uab Research Foundation |
Crispr/cas9 complex for introducing a functional polypeptide into cells of blood cell lineage
|
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
|
TWI813532B
(zh)
*
|
2015-06-18 |
2023-09-01 |
美商博得學院股份有限公司 |
降低脱靶效應的ｃｒｉｓｐｒ酶突變
|
|
CA3012607A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Crispr enzymes and systems
|
|
WO2016205745A2
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Cell sorting
|
|
EP4159856A1
(en)
|
2015-06-18 |
2023-04-05 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
US9790490B2
(en)
|
2015-06-18 |
2017-10-17 |
The Broad Institute Inc. |
CRISPR enzymes and systems
|
|
EP4545544A3
(en)
|
2015-06-29 |
2025-10-08 |
Ionis Pharmaceuticals, Inc. |
Modified crispr rna and modified single crispr rna and uses thereof
|
|
US20170000743A1
(en)
*
|
2015-07-02 |
2017-01-05 |
Vindico NanoBio Technology Inc. |
Compositions and Methods for Delivery of Gene Editing Tools Using Polymeric Vesicles
|
|
US10456452B2
(en)
|
2015-07-02 |
2019-10-29 |
Poseida Therapeutics, Inc. |
Compositions and methods for improved encapsulation of functional proteins in polymeric vesicles
|
|
GB2592821B
(en)
|
2015-07-31 |
2022-01-12 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
US9580727B1
(en)
|
2015-08-07 |
2017-02-28 |
Caribou Biosciences, Inc. |
Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotides
|
|
EP3331913A1
(en)
|
2015-08-07 |
2018-06-13 |
Novartis AG |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
EP4512819A3
(en)
|
2015-08-12 |
2025-08-06 |
The General Hospital Corporation |
Compositions and methods that promote hypoxia or the hypoxia response for treatment and prevention of mitochondrial dysfunction and oxidative stress disorders
|
|
CA3033909A1
(en)
|
2015-08-14 |
2017-02-23 |
The University Of Sydney |
Connexin 45 inhibition for therapy
|
|
WO2017031370A1
(en)
|
2015-08-18 |
2017-02-23 |
The Broad Institute, Inc. |
Methods and compositions for altering function and structure of chromatin loops and/or domains
|
|
AU2016316845B2
(en)
|
2015-08-28 |
2022-03-10 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
IL241462A0
(en)
|
2015-09-10 |
2015-11-30 |
Yeda Res & Dev |
Heterologous engineering of betalain pigments in plants
|
|
JP2018530536A
(ja)
|
2015-09-11 |
2018-10-18 |
ザ ジェネラル ホスピタル コーポレイション |
ヌクレアーゼＤＳＢの完全照合およびシーケンシング（ＦＩＮＤ−ｓｅｑ）
|
|
AU2016326711B2
(en)
|
2015-09-24 |
2022-11-03 |
Editas Medicine, Inc. |
Use of exonucleases to improve CRISPR/Cas-mediated genome editing
|
|
WO2017053729A1
(en)
|
2015-09-25 |
2017-03-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
Nuclease-mediated genome editing of primary cells and enrichment thereof
|
|
WO2017058791A1
(en)
*
|
2015-09-29 |
2017-04-06 |
Agenovir Corporation |
Compositions and methods for treatment of latent viral infections
|
|
JP2018529353A
(ja)
|
2015-09-30 |
2018-10-11 |
ザ ジェネラル ホスピタル コーポレイション |
配列決定法による切断事象の包括的生体外報告（ＣＩＲＣＬＥ−ｓｅｑ）
|
|
EP3356520B1
(en)
|
2015-10-02 |
2022-03-23 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Lentiviral protein delivery system for rna-guided genome editing
|
|
US12241053B2
(en)
|
2015-10-09 |
2025-03-04 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
CN109153980B
(zh)
|
2015-10-22 |
2023-04-14 |
布罗德研究所有限公司 |
Vi-b型crispr酶和系统
|
|
JP7109784B2
(ja)
|
2015-10-23 |
2022-08-01 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
遺伝子編集のための進化したＣａｓ９蛋白質
|
|
DK3350327T3
(en)
|
2015-10-23 |
2019-01-21 |
Caribou Biosciences Inc |
CONSTRUCTED CRISPR CLASS-2-NUCLEIC ACID TARGETING-NUCLEIC ACID
|
|
EP3368687B1
(en)
|
2015-10-27 |
2021-09-29 |
The Broad Institute, Inc. |
Compositions and methods for targeting cancer-specific sequence variations
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
WO2017075478A2
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
|
|
WO2017075294A1
(en)
|
2015-10-28 |
2017-05-04 |
The Board Institute Inc. |
Assays for massively combinatorial perturbation profiling and cellular circuit reconstruction
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
US11092607B2
(en)
|
2015-10-28 |
2021-08-17 |
The Board Institute, Inc. |
Multiplex analysis of single cell constituents
|
|
ES2905558T3
(es)
|
2015-11-13 |
2022-04-11 |
Avellino Lab Usa Inc |
Procedimientos para el tratamiento de las distrofias corneales
|
|
WO2017087885A1
(en)
|
2015-11-19 |
2017-05-26 |
Dana-Farber Cancer Institute, Inc. |
Methods of identifying compounds that interfere with erg-driven misguidance of baf complexes in tmprss2-erg driven prostate cancers
|
|
AU2016355178B9
(en)
|
2015-11-19 |
2019-05-30 |
Massachusetts Institute Of Technology |
Lymphocyte antigen CD5-like (CD5L)-interleukin 12B (p40) heterodimers in immunity
|
|
GB201520497D0
(en)
|
2015-11-20 |
2016-01-06 |
4D Pharma Res Ltd |
Compositions comprising bacterial strains
|
|
HK1254843B
(zh)
|
2015-11-20 |
2020-04-17 |
希杰生物科技株式会社 |
包含细菌菌株的组合物
|
|
JP2019500899A
(ja)
*
|
2015-11-23 |
2019-01-17 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
ＣＲＩＳＰＲ／Ｃａｓ９の核送達を通じた細胞ＲＮＡの追跡と操作
|
|
US11903974B2
(en)
|
2015-11-30 |
2024-02-20 |
Flagship Pioneering Innovations V, Inc. |
Methods and compositions relating to chondrisomes from cultured cells
|
|
WO2017095960A1
(en)
*
|
2015-11-30 |
2017-06-08 |
Synthetic Genomics, Inc. |
Compositions and methods for expressing genes in algae
|
|
WO2017093370A1
(en)
*
|
2015-12-03 |
2017-06-08 |
Technische Universität München |
T-cell specific genome editing
|
|
AU2016363024B2
(en)
|
2015-12-04 |
2020-01-30 |
Caribou Biosciences, Inc. |
Engineered nucleic-acid targeting nucleic acids
|
|
US11208649B2
(en)
|
2015-12-07 |
2021-12-28 |
Zymergen Inc. |
HTP genomic engineering platform
|
|
US9988624B2
(en)
|
2015-12-07 |
2018-06-05 |
Zymergen Inc. |
Microbial strain improvement by a HTP genomic engineering platform
|
|
JP6821598B2
(ja)
|
2015-12-07 |
2021-01-27 |
ザイマージェン インコーポレイテッド |
Ｃｏｒｙｎｅｂａｃｔｅｒｉｕｍ ｇｌｕｔａｍｉｃｕｍ由来のプロモーター
|
|
WO2017106657A1
(en)
|
2015-12-18 |
2017-06-22 |
The Broad Institute Inc. |
Novel crispr enzymes and systems
|
|
AU2016382512A1
(en)
|
2015-12-30 |
2018-07-12 |
Novartis Ag |
Immune effector cell therapies with enhanced efficacy
|
|
US11672866B2
(en)
|
2016-01-08 |
2023-06-13 |
Paul N. DURFEE |
Osteotropic nanoparticles for prevention or treatment of bone metastases
|
|
ES2875747T3
(es)
|
2016-01-11 |
2021-11-11 |
Univ Leland Stanford Junior |
Proteínas quiméricas y métodos de inmunoterapia
|
|
WO2017123559A2
(en)
|
2016-01-11 |
2017-07-20 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chimeric proteins and methods of regulating gene expression
|
|
SI4272834T1
(sl)
|
2016-01-15 |
2026-03-31 |
Beth Israel Deaconess Medical Center, Inc. |
Terapevtska uporaba mitohondrijev in kombiniranih mitohondrijskih sredstev
|
|
WO2017139309A1
(en)
|
2016-02-12 |
2017-08-17 |
Ceres, Inc. |
Methods and materials for high throughput testing of mutagenized allele combinations
|
|
US20190249172A1
(en)
|
2016-02-18 |
2019-08-15 |
The Regents Of The University Of California |
Methods and compositions for gene editing in stem cells
|
|
WO2017147196A1
(en)
|
2016-02-22 |
2017-08-31 |
Massachusetts Institute Of Technology |
Methods for identifying and modulating immune phenotypes
|
|
CN105543195A
(zh)
*
|
2016-03-01 |
2016-05-04 |
中国水稻研究所 |
植物Cas9变体蛋白VQR及其编码基因与应用
|
|
CN105543196A
(zh)
*
|
2016-03-01 |
2016-05-04 |
中国水稻研究所 |
植物Cas9变体蛋白VRER及其编码基因与应用
|
|
CA3016571A1
(en)
|
2016-03-04 |
2017-09-08 |
Indoor Biotechnologies Inc. |
Fel d 1 knockouts and associated compositions and methods based on crispr-cas9 genomic editing
|
|
GB201612191D0
(en)
|
2016-07-13 |
2016-08-24 |
4D Pharma Plc |
Compositions comprising bacterial strains
|
|
SG10201913557TA
(en)
|
2016-03-04 |
2020-02-27 |
4D Pharma Plc |
Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
|
|
WO2017161043A1
(en)
|
2016-03-16 |
2017-09-21 |
The J. David Gladstone Institutes |
Methods and compositions for treating obesity and/or diabetes and for identifying candidate treatment agents
|
|
EP3219799A1
(en)
|
2016-03-17 |
2017-09-20 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Conditional crispr sgrna expression
|
|
US11427861B2
(en)
|
2016-03-17 |
2022-08-30 |
Massachusetts Institute Of Technology |
Methods for identifying and modulating co-occurant cellular phenotypes
|
|
US20200291370A1
(en)
*
|
2016-03-18 |
2020-09-17 |
President And Fellows Of Harvard College |
Mutant Cas Proteins
|
|
WO2017165859A1
(en)
*
|
2016-03-24 |
2017-09-28 |
Research Institute At Nationwide Children's Hospital |
Modified viral capsid proteins
|
|
WO2017165862A1
(en)
|
2016-03-25 |
2017-09-28 |
Editas Medicine, Inc. |
Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
|
|
EP3433363A1
(en)
|
2016-03-25 |
2019-01-30 |
Editas Medicine, Inc. |
Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
|
|
WO2017180694A1
(en)
|
2016-04-13 |
2017-10-19 |
Editas Medicine, Inc. |
Cas9 fusion molecules gene editing systems, and methods of use thereof
|
|
MY209117A
(en)
|
2016-04-15 |
2025-06-23 |
Novartis Ag |
Compositions and methods for selective protein expression
|
|
EP3445853A1
(en)
|
2016-04-19 |
2019-02-27 |
The Broad Institute, Inc. |
Cpf1 complexes with reduced indel activity
|
|
CN110382692A
(zh)
|
2016-04-19 |
2019-10-25 |
博德研究所 |
新型crispr酶以及系统
|
|
US20200263190A1
(en)
|
2016-04-19 |
2020-08-20 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
CN107304435A
(zh)
*
|
2016-04-22 |
2017-10-31 |
中国科学院青岛生物能源与过程研究所 |
一种Cas9/RNA系统及其应用
|
|
ES2865481T3
(es)
|
2016-04-29 |
2021-10-15 |
Poseida Therapeutics Inc |
Micelas basadas en poli(histidina) para la complejación y el aporte de proteínas y ácidos nucleicos
|
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
|
CA3028158A1
(en)
|
2016-06-17 |
2017-12-21 |
The Broad Institute, Inc. |
Type vi crispr orthologs and systems
|
|
US10017760B2
(en)
|
2016-06-24 |
2018-07-10 |
Inscripta, Inc. |
Methods for generating barcoded combinatorial libraries
|
|
MX2019000088A
(es)
|
2016-06-27 |
2019-08-29 |
Broad Inst Inc |
Composiciones y metodos para detectar y tratar la diabetes.
|
|
US12595478B2
(en)
|
2016-06-29 |
2026-04-07 |
The Broad Institute, Inc. |
Crispr-Cas systems having destabilization domain
|
|
EP3478833A4
(en)
|
2016-06-30 |
2019-10-02 |
Zymergen, Inc. |
METHOD FOR PRODUCING A BACTERIAL HEMOGLOBIN LIBRARY AND ITS USE
|
|
JP2019519241A
(ja)
|
2016-06-30 |
2019-07-11 |
ザイマージェン インコーポレイテッド |
グルコース透過酵素ライブラリーを生成するための方法およびその使用
|
|
TWI802545B
(zh)
|
2016-07-13 |
2023-05-21 |
英商４Ｄ製藥有限公司 |
包含細菌菌株之組合物
|
|
EP3484870B1
(en)
|
2016-07-13 |
2022-11-16 |
Vertex Pharmaceuticals Incorporated |
Methods, compositions and kits for increasing genome editing efficiency
|
|
US20190336504A1
(en)
|
2016-07-15 |
2019-11-07 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
WO2018026976A1
(en)
|
2016-08-02 |
2018-02-08 |
Editas Medicine, Inc. |
Compositions and methods for treating cep290 associated disease
|
|
KR102547316B1
(ko)
|
2016-08-03 |
2023-06-23 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
아데노신 핵염기 편집제 및 그의 용도
|
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
|
US11661590B2
(en)
|
2016-08-09 |
2023-05-30 |
President And Fellows Of Harvard College |
Programmable CAS9-recombinase fusion proteins and uses thereof
|
|
BR112019002779A2
(pt)
*
|
2016-08-12 |
2019-05-14 |
Toolgen Incorporated |
elemento imunorregulador manipulado e imunidade alterada por este
|
|
US12431216B2
(en)
|
2016-08-17 |
2025-09-30 |
Broad Institute, Inc. |
Methods for identifying class 2 crispr-cas systems
|
|
CN110312799A
(zh)
|
2016-08-17 |
2019-10-08 |
博德研究所 |
新型crispr酶和系统
|
|
US11630103B2
(en)
|
2016-08-17 |
2023-04-18 |
The Broad Institute, Inc. |
Product and methods useful for modulating and evaluating immune responses
|
|
WO2018035388A1
(en)
|
2016-08-17 |
2018-02-22 |
The Broad Institute, Inc. |
Novel crispr enzymes and systems
|
|
CN109844123A
(zh)
*
|
2016-08-19 |
2019-06-04 |
株式会社图尔金 |
经人工操纵的血管生成调控系统
|
|
WO2020225754A1
(en)
|
2019-05-06 |
2020-11-12 |
Mcmullen Tara |
Crispr gene editing for autosomal dominant diseases
|
|
JP2019524149A
(ja)
|
2016-08-20 |
2019-09-05 |
アベリノ ラボ ユーエスエー インコーポレイテッドＡｖｅｌｌｉｎｏ Ｌａｂ ＵＳＡ， Ｉｎｃ． |
一本鎖ガイドＲＮＡ、ＣＲＩＳＰＲ／Ｃａｓ９システム、及びそれらの使用方法
|
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
|
EP3510145A4
(en)
|
2016-09-06 |
2020-03-25 |
The Children's Medical Center Corporation |
IMMUNCELLS FROM INDUCED PLURIPOTENT STEM CELLS
|
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
EP4431607A3
(en)
|
2016-09-09 |
2024-12-11 |
The Board of Trustees of the Leland Stanford Junior University |
High-throughput precision genome editing
|
|
IL247752A0
(en)
|
2016-09-11 |
2016-11-30 |
Yeda Res & Dev |
Compositions and methods for modulating gene expression for site-directed mutagenesis
|
|
US20190225974A1
(en)
|
2016-09-23 |
2019-07-25 |
BASF Agricultural Solutions Seed US LLC |
Targeted genome optimization in plants
|
|
JP2019532672A
(ja)
|
2016-09-28 |
2019-11-14 |
ノバルティス アーゲー |
多孔質膜系巨大分子送達システム
|
|
WO2018064208A1
(en)
|
2016-09-28 |
2018-04-05 |
The Broad Institute, Inc. |
Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
|
|
CA3038960A1
(en)
|
2016-09-30 |
2018-04-05 |
The Regents Of The University Of California |
Rna-guided nucleic acid modifying enzymes and methods of use thereof
|
|
US10669539B2
(en)
|
2016-10-06 |
2020-06-02 |
Pioneer Biolabs, Llc |
Methods and compositions for generating CRISPR guide RNA libraries
|
|
US12447213B2
(en)
|
2016-10-07 |
2025-10-21 |
The Broad Institute, Inc. |
Modulation of novel immune checkpoint targets
|
|
EP3526320A1
(en)
*
|
2016-10-14 |
2019-08-21 |
President and Fellows of Harvard College |
Aav delivery of nucleobase editors
|
|
GB201617559D0
(en)
|
2016-10-17 |
2016-11-30 |
University Court Of The University Of Edinburgh The |
Swine comprising modified cd163 and associated methods
|
|
JP7181862B2
(ja)
|
2016-10-18 |
2022-12-01 |
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ |
腫瘍浸潤リンパ球および治療の方法
|
|
WO2018081531A2
(en)
|
2016-10-28 |
2018-05-03 |
Ariad Pharmaceuticals, Inc. |
Methods for human t-cell activation
|
|
EP3532614A1
(en)
*
|
2016-10-28 |
2019-09-04 |
Genethon |
Compositions and methods for the treatment of myotonic dystrophy
|
|
US20180245065A1
(en)
|
2016-11-01 |
2018-08-30 |
Novartis Ag |
Methods and compositions for enhancing gene editing
|
|
WO2018085693A1
(en)
|
2016-11-04 |
2018-05-11 |
Inari Agriculture, Inc. |
Novel plant cells, plants, and seeds
|
|
WO2018089386A1
(en)
|
2016-11-11 |
2018-05-17 |
The Broad Institute, Inc. |
Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
|
|
US9816093B1
(en)
|
2016-12-06 |
2017-11-14 |
Caribou Biosciences, Inc. |
Engineered nucleic acid-targeting nucleic acids
|
|
US12404514B2
(en)
|
2016-12-09 |
2025-09-02 |
The Broad Institute, Inc. |
CRISPR-systems for modifying a trait of interest in a plant
|
|
GB201621123D0
(en)
|
2016-12-12 |
2017-01-25 |
4D Pharma Plc |
Compositions comprising bacterial strains
|
|
US11674128B2
(en)
*
|
2016-12-12 |
2023-06-13 |
Tsinghua University |
Engineering of a minimal SaCas9 CRISPR/Cas system for gene editing and transcriptional regulation optimized by enhanced guide RNA
|
|
CN110582301A
(zh)
|
2016-12-14 |
2019-12-17 |
利甘达尔股份有限公司 |
用于核酸和蛋白质有效负载递送的方法和组合物
|
|
WO2018119010A1
(en)
|
2016-12-19 |
2018-06-28 |
Editas Medicine, Inc. |
Assessing nuclease cleavage
|
|
CN110213961A
(zh)
|
2016-12-22 |
2019-09-06 |
孟山都技术公司 |
基于基因组编辑的作物工程化和生产矮秆植物
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
US11859219B1
(en)
|
2016-12-30 |
2024-01-02 |
Flagship Pioneering Innovations V, Inc. |
Methods of altering a target nucleotide sequence with an RNA-guided nuclease and a single guide RNA
|
|
WO2018127585A1
(en)
|
2017-01-06 |
2018-07-12 |
Txcell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
|
EP3346001A1
(en)
|
2017-01-06 |
2018-07-11 |
TXCell |
Monospecific regulatory t cell population with cytotoxicity for b cells
|
|
EP3565907B1
(en)
|
2017-01-06 |
2022-05-04 |
Editas Medicine, Inc. |
Methods of assessing nuclease cleavage
|
|
EP3565891B1
(en)
|
2017-01-09 |
2023-04-12 |
Whitehead Institute for Biomedical Research |
Methods of altering gene expression by perturbing transcription factor multimers that structure regulatory loops
|
|
EP4043485A1
(en)
|
2017-01-26 |
2022-08-17 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
US11624071B2
(en)
|
2017-01-28 |
2023-04-11 |
Inari Agriculture Technology, Inc. |
Method of creating a plurality of targeted insertions in a plant cell
|
|
CN110582509A
(zh)
|
2017-01-31 |
2019-12-17 |
诺华股份有限公司 |
使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
|
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
|
EP3580337A4
(en)
|
2017-02-10 |
2020-12-02 |
Zymergen, Inc. |
MODULAR UNIVERSAL PLASMID DESIGN STRATEGY FOR ASSEMBLY AND EDITING MULTIPLE MULTI-HOST DNA CONSTRUCTIONS
|
|
EP3589647A1
(en)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
WO2018160865A1
(en)
|
2017-03-01 |
2018-09-07 |
Charles Jeffrey Brinker |
Active targeting of cells by monosized protocells
|
|
GB2574769A
(en)
|
2017-03-03 |
2019-12-18 |
Univ California |
RNA Targeting of mutations via suppressor tRNAs and deaminases
|
|
JP2020510038A
(ja)
|
2017-03-09 |
2020-04-02 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
がんワクチン
|
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
|
EP3596217A1
(en)
|
2017-03-14 |
2020-01-22 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
AU2018234825B2
(en)
|
2017-03-15 |
2020-12-17 |
Massachusetts Institute Of Technology |
Novel CAS13B orthologues CRISPR enzymes and systems
|
|
US12180546B2
(en)
|
2017-03-17 |
2024-12-31 |
Massachusetts Institute Of Technology |
Methods for identifying and modulating co-occurant cellular phenotypes
|
|
CA3057192A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
|
US12161694B2
(en)
|
2017-03-24 |
2024-12-10 |
The Broad Institute, Inc. |
Methods and compositions for regulating innate lymphoid cell inflammatory responses
|
|
WO2018183908A1
(en)
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
|
EP3606518A4
(en)
|
2017-04-01 |
2021-04-07 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTION AND MODULATION OF IMMUNOTHERAPY RESISTANCE GENE SIGNATURE IN CANCER
|
|
AU2018251801B2
(en)
|
2017-04-12 |
2024-11-07 |
Massachusetts Institute Of Technology |
Novel type VI CRISPR orthologs and systems
|
|
US12331319B2
(en)
|
2017-04-12 |
2025-06-17 |
The Broad Institute, Inc. |
Respiratory and sweat gland ionocytes
|
|
WO2018191558A1
(en)
|
2017-04-12 |
2018-10-18 |
The Broad Institute, Inc. |
Modulation of epithelial cell differentiation, maintenance and/or function through t cell action, and markers and methods of use thereof
|
|
US20200071773A1
(en)
|
2017-04-12 |
2020-03-05 |
Massachusetts Eye And Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
|
US12350368B2
(en)
|
2017-04-14 |
2025-07-08 |
The Broad Institute, Inc. |
Delivery of large payloads
|
|
US20210293783A1
(en)
|
2017-04-18 |
2021-09-23 |
The General Hospital Corporation |
Compositions for detecting secretion and methods of use
|
|
WO2018195402A1
(en)
|
2017-04-20 |
2018-10-25 |
Egenesis, Inc. |
Methods for generating genetically modified animals
|
|
WO2018195545A2
(en)
|
2017-04-21 |
2018-10-25 |
The General Hospital Corporation |
Variants of cpf1 (cas12a) with altered pam specificity
|
|
WO2018195486A1
(en)
|
2017-04-21 |
2018-10-25 |
The Broad Institute, Inc. |
Targeted delivery to beta cells
|
|
US11499151B2
(en)
|
2017-04-28 |
2022-11-15 |
Editas Medicine, Inc. |
Methods and systems for analyzing guide RNA molecules
|
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
US11591601B2
(en)
|
2017-05-05 |
2023-02-28 |
The Broad Institute, Inc. |
Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
|
|
JP7235391B2
(ja)
*
|
2017-05-08 |
2023-03-08 |
ツールゲン インコーポレイテッド |
人工的に操作された免疫細胞
|
|
EP3622062A4
(en)
|
2017-05-10 |
2020-10-14 |
The Regents of the University of California |
DIRECTED EDITING OF CELLULAR RNA BY NUCLEAR ADMINISTRATION OF CRISPR / CAS9
|
|
EP3622070A2
(en)
|
2017-05-10 |
2020-03-18 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease systems and methods
|
|
EP3622092A4
(en)
|
2017-05-11 |
2021-06-23 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
|
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
|
US11692184B2
(en)
|
2017-05-16 |
2023-07-04 |
The Regents Of The University Of California |
Thermostable RNA-guided endonucleases and methods of use thereof
|
|
EP3625342B1
(en)
|
2017-05-18 |
2022-08-24 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
WO2018213708A1
(en)
|
2017-05-18 |
2018-11-22 |
The Broad Institute, Inc. |
Systems, methods, and compositions for targeted nucleic acid editing
|
|
ES2877726T3
(es)
|
2017-05-22 |
2021-11-17 |
4D Pharma Res Ltd |
Composiciones que comprenden cepas bacterianas
|
|
EP3630942B1
(en)
|
2017-05-24 |
2022-11-30 |
4D Pharma Research Limited |
Compositions comprising bacterial strain
|
|
US20200172895A1
(en)
|
2017-05-25 |
2020-06-04 |
The General Hospital Corporation |
Using split deaminases to limit unwanted off-target base editor deamination
|
|
EP3630975B1
(en)
*
|
2017-05-26 |
2025-11-19 |
North Carolina State University |
Altered guide rnas for modulating cas9 activity and methods of use
|
|
EP3409104A1
(en)
|
2017-05-31 |
2018-12-05 |
Vilmorin et Cie |
Tomato plant resistant to tomato yellow leaf curl virus, powdery mildew, and nematodes
|
|
WO2020249996A1
(en)
|
2019-06-14 |
2020-12-17 |
Vilmorin & Cie |
Resistance in plants of solanum lycopersicum to the tobamovirus tomato brown rugose fruit virus
|
|
EP3409106A1
(en)
|
2017-06-01 |
2018-12-05 |
Vilmorin et Cie |
Tolerance in plants of solanum lycopersicum to the tobamovirus tomato brown rugose fruit virus (tbrfv)
|
|
CA3065946A1
(en)
|
2017-06-05 |
2018-12-13 |
Research Institute At Nationwide Children's Hospital |
Enhanced modified viral capsid proteins
|
|
CA3102054A1
(en)
|
2017-06-05 |
2018-12-13 |
Fred Hutchinson Cancer Research Center |
Genomic safe harbors for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies
|
|
KR20200026874A
(ko)
|
2017-06-06 |
2020-03-11 |
지머젠 인코포레이티드 |
대장균 개량을 위한 htp 게놈 공학 플랫폼
|
|
KR20200026878A
(ko)
|
2017-06-06 |
2020-03-11 |
지머젠 인코포레이티드 |
균류 균주를 개량하기 위한 htp 게놈 공학 플랫폼
|
|
AU2018279112B2
(en)
*
|
2017-06-07 |
2024-11-07 |
Arc Bio, Llc |
Creation and use of guide nucleic acids
|
|
WO2018227114A1
(en)
|
2017-06-09 |
2018-12-13 |
Editas Medicine, Inc. |
Engineered cas9 nucleases
|
|
IL271275B1
(en)
|
2017-06-13 |
2026-04-01 |
Flagship Pioneering Innovations V Inc |
Preparations containing croons and their uses
|
|
TWI812624B
(zh)
|
2017-06-14 |
2023-08-21 |
南韓商希杰生物科技股份有限公司 |
包含細菌品系之組成物
|
|
WO2018232195A1
(en)
|
2017-06-14 |
2018-12-20 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
ES2841902T3
(es)
|
2017-06-14 |
2021-07-12 |
4D Pharma Res Ltd |
Composiciones que comprenden cepas bacterianas
|
|
WO2018232114A1
(en)
|
2017-06-14 |
2018-12-20 |
Wisconsin Alumni Research Foundation |
Modified guide rnas, crispr-ribonucleotprotein complexes and methods of use
|
|
PL3600363T3
(pl)
|
2017-06-14 |
2021-06-14 |
4D Pharma Research Limited |
Kompozycje zawierające szczepy bakteryjne
|
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
|
AU2018290843B2
(en)
|
2017-06-26 |
2025-04-24 |
Massachusetts Institute Of Technology |
CRISPR/Cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing
|
|
WO2019006418A2
(en)
|
2017-06-30 |
2019-01-03 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
|
WO2019003193A1
(en)
|
2017-06-30 |
2019-01-03 |
Novartis Ag |
METHODS FOR TREATING DISEASES USING GENE EDITING SYSTEMS
|
|
US12049643B2
(en)
|
2017-07-14 |
2024-07-30 |
The Broad Institute, Inc. |
Methods and compositions for modulating cytotoxic lymphocyte activity
|
|
US11866726B2
(en)
|
2017-07-14 |
2024-01-09 |
Editas Medicine, Inc. |
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
|
|
EP3654993A4
(en)
|
2017-07-17 |
2021-08-25 |
The Broad Institute, Inc. |
CELL ATLAS OF HEALTHY HUMAN COLUMN AND HUMAN COLUMN WITH COLITIS ULCEROSA
|
|
US20190316101A1
(en)
|
2017-07-18 |
2019-10-17 |
Howard Hughes Medical Institute |
Methods and compositions for genetically manipulating genes and cells
|
|
US12239646B2
(en)
|
2017-07-19 |
2025-03-04 |
Dana-Farber Cancer Institute, Inc. |
Cancer diagnostic and treatment
|
|
WO2019023291A2
(en)
|
2017-07-25 |
2019-01-31 |
Dana-Farber Cancer Institute, Inc. |
COMPOSITIONS AND METHODS FOR PRODUCTION AND DECODING OF GUIDE RNA LIBRARIES AND USES THEREOF
|
|
WO2019023680A1
(en)
|
2017-07-28 |
2019-01-31 |
President And Fellows Of Harvard College |
METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
|
|
KR20200036912A
(ko)
|
2017-07-31 |
2020-04-07 |
리플렉션 바이오테크놀러지스 리미티드 |
안과 질환을 위한 세포 모델 및 치료요법
|
|
CN118530967A
(zh)
|
2017-08-23 |
2024-08-23 |
通用医疗公司 |
具有改变的PAM特异性的工程化的CRISPR-Cas9核酸酶
|
|
EP3676376B1
(en)
|
2017-08-30 |
2025-01-15 |
President and Fellows of Harvard College |
High efficiency base editors comprising gam
|
|
US11713452B2
(en)
|
2017-09-08 |
2023-08-01 |
University Of North Texas Health Science Center |
Engineered CAS9 variants
|
|
US20190076814A1
(en)
|
2017-09-11 |
2019-03-14 |
Synthego Corporation |
Biopolymer synthesis system and method
|
|
CA3076261A1
(en)
|
2017-09-19 |
2019-03-28 |
Admare Vintageco1 Investments Ltd. |
Anti-hla-a2 antibodies and methods of using the same
|
|
IT201700105372A1
(it)
*
|
2017-09-20 |
2019-03-20 |
Fondazione St Italiano Tecnologia |
Molecola di acido nucleico funzionale e relativo uso
|
|
EP3684822A4
(en)
|
2017-09-20 |
2021-06-16 |
The University of British Columbia |
NEW ANTI-HLA-A2 ANTIBODIES AND USES THEREOF
|
|
CA3076249A1
(en)
|
2017-09-21 |
2019-03-28 |
The Brigham And Women's Hospital, Inc. |
Isolation, preservation, compositions and uses of extracts from justicia plants
|
|
JP2020535802A
(ja)
|
2017-09-21 |
2020-12-10 |
ザ・ブロード・インスティテュート・インコーポレイテッド |
標的化核酸編集のための系、方法、及び組成物
|
|
BR112020005803A2
(pt)
|
2017-09-25 |
2020-12-01 |
Agrospheres, Inc. |
composições e métodos para produção e administração moduláveis de produtos biológicos
|
|
US10933027B1
(en)
|
2017-09-25 |
2021-03-02 |
National Technology & Engineering Solutions Of Sandia, Llc |
Expanded pore particles and delivery methods thereof
|
|
EP3695408B1
(en)
|
2017-10-02 |
2026-01-21 |
The Broad Institute, Inc. |
Medical use of cdk4/6- and checkpoint-inhibitors in phased combination, in treatment of cancer
|
|
EP3692152B1
(en)
|
2017-10-04 |
2025-09-03 |
The Broad Institute, Inc. |
Methods and compositions for altering function and structure of chromatin loops and/or domains
|
|
WO2019075197A1
(en)
|
2017-10-11 |
2019-04-18 |
The General Hospital Corporation |
METHODS OF DETECTION OF INDIVIDUAL SITE-SPECIFIC PARASITE GENOMIC DEAMINATION BY BASE EDITING TECHNOLOGIES
|
|
KR20250107288A
(ko)
|
2017-10-16 |
2025-07-11 |
더 브로드 인스티튜트, 인코퍼레이티드 |
아데노신 염기 편집제의 용도
|
|
WO2019079362A1
(en)
|
2017-10-16 |
2019-04-25 |
Massachusetts Institute Of Technology |
HOST-PATHOGENIC INTERACTION OF MYCOBACTERIUM TUBERCULOSIS
|
|
MX2020004063A
(es)
|
2017-10-20 |
2020-10-05 |
Hutchinson Fred Cancer Res |
Sistemas y metodos para producir celulas b modificadas geneticamente para expresar anticuerpos seleccionados.
|
|
US12227742B2
(en)
|
2017-10-23 |
2025-02-18 |
The Broad Institute, Inc. |
Nucleic acid modifiers
|
|
US20210179709A1
(en)
|
2017-10-31 |
2021-06-17 |
Novartis Ag |
Anti-car compositions and methods
|
|
US11547614B2
(en)
|
2017-10-31 |
2023-01-10 |
The Broad Institute, Inc. |
Methods and compositions for studying cell evolution
|
|
WO2019087113A1
(en)
|
2017-11-01 |
2019-05-09 |
Novartis Ag |
Synthetic rnas and methods of use
|
|
EP3710039A4
(en)
|
2017-11-13 |
2021-08-04 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
|
|
WO2019094984A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods for determining spatial and temporal gene expression dynamics during adult neurogenesis in single cells
|
|
WO2019094955A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
|
|
CN111448313A
(zh)
|
2017-11-16 |
2020-07-24 |
阿斯利康(瑞典)有限公司 |
用于改善基于Cas9的敲入策略的有效性的组合物和方法
|
|
EP4501408A3
(en)
|
2017-11-17 |
2025-04-09 |
Iovance Biotherapeutics, Inc. |
Til expansion from fine needle aspirates and small biopsies
|
|
EP3714041A1
(en)
|
2017-11-22 |
2020-09-30 |
Iovance Biotherapeutics, Inc. |
Expansion of peripheral blood lymphocytes (pbls) from peripheral blood
|
|
WO2019113506A1
(en)
|
2017-12-07 |
2019-06-13 |
The Broad Institute, Inc. |
Methods and compositions for multiplexing single cell and single nuclei sequencing
|
|
CN109912702B
(zh)
*
|
2017-12-13 |
2021-03-16 |
中国科学院遗传与发育生物学研究所 |
蛋白质OsARE1在调控植物抗低氮性中的应用
|
|
JP2021506251A
(ja)
|
2017-12-14 |
2021-02-22 |
クリスパー セラピューティクス アーゲー |
新規ｒｎａプログラム可能エンドヌクレアーゼ系、ならびにゲノム編集および他の適用におけるその使用
|
|
WO2019118949A1
(en)
|
2017-12-15 |
2019-06-20 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
WO2019126709A1
(en)
|
2017-12-22 |
2019-06-27 |
The Broad Institute, Inc. |
Cas12b systems, methods, and compositions for targeted dna base editing
|
|
WO2019133881A1
(en)
|
2017-12-29 |
2019-07-04 |
Rubius Therapeutics, Inc. |
Gene editing and targeted transcriptional modulation for enginerering erythroid cells
|
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
|
CA3086620A1
(en)
|
2018-01-12 |
2019-07-18 |
Basf Se |
Gene underlying the number of spikelets per spike qtl in wheat on chromosome 7a
|
|
MA51619A
(fr)
|
2018-01-17 |
2021-04-14 |
Vertex Pharma |
Inhibiteurs de la protéine kinase dépendante de l'adn
|
|
CA3088788A1
(en)
|
2018-01-17 |
2019-07-25 |
Vertex Pharmaceuticals Incorporated |
Dna-pk inhibitors
|
|
JP7483612B2
(ja)
|
2018-01-17 |
2024-05-15 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ゲノム編集効率を増加するためのキノキサリノン化合物、組成物、方法、およびキット
|
|
WO2019147743A1
(en)
|
2018-01-26 |
2019-08-01 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide rna and its applications
|
|
US11926835B1
(en)
|
2018-01-29 |
2024-03-12 |
Inari Agriculture Technology, Inc. |
Methods for efficient tomato genome editing
|
|
WO2019152437A1
(en)
|
2018-01-30 |
2019-08-08 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
WO2019157326A1
(en)
|
2018-02-08 |
2019-08-15 |
Zymergen Inc. |
Genome editing using crispr in corynebacterium
|
|
KR20200124702A
(ko)
|
2018-02-23 |
2020-11-03 |
파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 |
신규한 cas9 오르소로그
|
|
WO2019178426A1
(en)
|
2018-03-14 |
2019-09-19 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
JP7550648B2
(ja)
|
2018-03-19 |
2024-09-13 |
クリスパー セラピューティクス アーゲー |
新規ｒｎａプログラム可能エンドヌクレアーゼ系およびその使用
|
|
AU2019247490A1
(en)
|
2018-04-06 |
2020-10-22 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
|
SG11202010116PA
(en)
|
2018-04-13 |
2020-11-27 |
Sangamo Therapeutics France |
Chimeric antigen receptor specific for interleukin-23 receptor
|
|
CA3097044A1
(en)
|
2018-04-17 |
2019-10-24 |
The General Hospital Corporation |
Sensitive in vitro assays for substrate preferences and sites of nucleic acid binding, modifying, and cleaving agents
|
|
US12338486B2
(en)
|
2018-04-19 |
2025-06-24 |
Massachusetts Institute Of Technology |
Single-stranded break detection in double-stranded DNA
|
|
JP7555822B2
(ja)
|
2018-04-19 |
2024-09-25 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア |
ゲノム編集のための組成物および方法
|
|
DK3560330T3
(da)
|
2018-04-24 |
2022-07-11 |
Kws Saat Se & Co Kgaa |
Planter med forbedret fordøjelighed og markørhaplotyper
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
US20210130779A1
(en)
|
2018-04-27 |
2021-05-06 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
WO2019210268A2
(en)
|
2018-04-27 |
2019-10-31 |
The Broad Institute, Inc. |
Sequencing-based proteomics
|
|
SG11202010631UA
(en)
|
2018-04-27 |
2020-11-27 |
Genedit Inc |
Cationic polymer and use for biomolecule delivery
|
|
EP3784351A1
(en)
|
2018-04-27 |
2021-03-03 |
Novartis AG |
Car t cell therapies with enhanced efficacy
|
|
US20210386829A1
(en)
|
2018-05-04 |
2021-12-16 |
The Broad Institute, Inc. |
Compositions and methods for modulating cgrp signaling to regulate innate lymphoid cell inflammatory responses
|
|
WO2019217803A1
(en)
|
2018-05-10 |
2019-11-14 |
Auxolytic Ltd. |
Gene therapy methods and compositions using auxotrophic regulatable cells
|
|
KR20210045360A
(ko)
|
2018-05-16 |
2021-04-26 |
신테고 코포레이션 |
가이드 rna 설계 및 사용을 위한 방법 및 시스템
|
|
EP3797160A1
(en)
|
2018-05-23 |
2021-03-31 |
The Broad Institute Inc. |
Base editors and uses thereof
|
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
|
US11866719B1
(en)
|
2018-06-04 |
2024-01-09 |
Inari Agriculture Technology, Inc. |
Heterologous integration of regulatory elements to alter gene expression in wheat cells and wheat plants
|
|
WO2019241315A1
(en)
|
2018-06-12 |
2019-12-19 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
US12227776B2
(en)
|
2018-06-13 |
2025-02-18 |
Caribou Biosciences, Inc. |
Engineered cascade components and cascade complexes
|
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
|
US10227576B1
(en)
|
2018-06-13 |
2019-03-12 |
Caribou Biosciences, Inc. |
Engineered cascade components and cascade complexes
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
US11045554B1
(en)
|
2018-06-22 |
2021-06-29 |
National Technology & Engineering Solutions Of Sandia, Llc |
Lipid-coated particles for treating viral infections
|
|
CA3102163A1
(en)
|
2018-06-26 |
2020-01-02 |
Massachusetts Institute Of Technology |
Crispr effector system based amplification methods, systems, and diagnostics
|
|
SG11202011240YA
(en)
|
2018-06-26 |
2020-12-30 |
Broad Inst Inc |
Crispr/cas and transposase based amplification compositions, systems and methods
|
|
EP3823633A4
(en)
|
2018-06-29 |
2023-05-03 |
Editas Medicine, Inc. |
SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO
|
|
WO2020002592A1
(en)
|
2018-06-29 |
2020-01-02 |
Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis |
Traf2 inhibitors for use in the treatment of a cancer
|
|
US12522807B2
(en)
|
2018-07-09 |
2026-01-13 |
The Broad Institute, Inc. |
RNA programmable epigenetic RNA modifiers and uses thereof
|
|
JP2021530212A
(ja)
|
2018-07-13 |
2021-11-11 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California |
レトロトランスポゾンベースの送達媒体及びその使用方法
|
|
CN113348245A
(zh)
|
2018-07-31 |
2021-09-03 |
博德研究所 |
新型crispr酶和系统
|
|
CN113286884A
(zh)
|
2018-08-07 |
2021-08-20 |
博德研究所 |
新型cas12b酶和系统
|
|
EP3607819A1
(en)
|
2018-08-10 |
2020-02-12 |
Vilmorin et Cie |
Resistance to xanthomonas campestris pv. campestris (xcc) in cauliflower
|
|
WO2020030979A2
(en)
|
2018-08-10 |
2020-02-13 |
Sangamo Therapeutics France |
New car constructs comprising tnfr2 domains
|
|
CA3107002A1
(en)
|
2018-08-15 |
2020-04-30 |
Zymergen Inc. |
Applications of crispri in high throughput metabolic engineering
|
|
US20210324357A1
(en)
|
2018-08-20 |
2021-10-21 |
The Brigham And Women's Hospital, Inc. |
Degradation domain modifications for spatio-temporal control of rna-guided nucleases
|
|
WO2020041380A1
(en)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
Methods and compositions for optochemical control of crispr-cas9
|
|
US12275964B2
(en)
|
2018-08-22 |
2025-04-15 |
The Regents Of The University Of California |
Variant type V CRISPR/Cas effector polypeptides and methods of use thereof
|
|
JP7541508B2
(ja)
|
2018-08-23 |
2024-08-28 |
サンガモ セラピューティクス， インコーポレイテッド |
操作された標的特異的な塩基エディター
|
|
CN113286880A
(zh)
|
2018-08-28 |
2021-08-20 |
旗舰先锋创新Vi有限责任公司 |
调控基因组的方法和组合物
|
|
US12545910B2
(en)
|
2018-08-31 |
2026-02-10 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
|
US12534743B2
(en)
|
2018-08-31 |
2026-01-27 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
|
US11479762B1
(en)
|
2018-08-31 |
2022-10-25 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
|
US20210317479A1
(en)
|
2018-09-06 |
2021-10-14 |
The Broad Institute, Inc. |
Nucleic acid assemblies for use in targeted delivery
|
|
EP3847251A1
(en)
|
2018-09-07 |
2021-07-14 |
Astrazeneca AB |
Compositions and methods for improved nucleases
|
|
EP3849565A4
(en)
|
2018-09-12 |
2022-12-28 |
Fred Hutchinson Cancer Research Center |
REDUCTION OF CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS
|
|
JP7344300B2
(ja)
|
2018-09-18 |
2023-09-13 |
ブイエヌブイ ニューコ インク． |
Ａｒｃベースのカプシドおよびその使用
|
|
US12097239B2
(en)
|
2018-09-21 |
2024-09-24 |
President And Fellows Of Harvard College |
Methods and compositions for treating diabetes, and methods for enriching MRNA coding for secreted proteins
|
|
WO2020068798A1
(en)
|
2018-09-24 |
2020-04-02 |
Guo Jimin |
Living mammalian cells modified with functional modular nanoparticles
|
|
EP3868887A4
(en)
*
|
2018-09-25 |
2022-12-07 |
Microbial Chemistry Research Foundation |
NOVEL VIRAL VECTOR AND METHODS OF PRODUCTION AND USE THEREOF
|
|
US20220411783A1
(en)
|
2018-10-12 |
2022-12-29 |
The Broad Institute, Inc. |
Method for extracting nuclei or whole cells from formalin-fixed paraffin-embedded tissues
|
|
US20210379057A1
(en)
|
2018-10-16 |
2021-12-09 |
Massachusetts Institute Of Technology |
Nutlin-3a for use in treating a mycobacterium tuberculosis infection
|
|
JP7578590B2
(ja)
|
2018-10-18 |
2024-11-06 |
インテリア セラピューティクス，インコーポレーテッド |
第ｉｘ因子を発現するための組成物及び方法
|
|
US20210395709A1
(en)
*
|
2018-10-18 |
2021-12-23 |
Chan Zuckerberg Biohub, Inc. |
Methods and compositions involving thermostable cas9 protein variants
|
|
WO2020086742A1
(en)
|
2018-10-24 |
2020-04-30 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
|
US12116458B2
(en)
|
2018-10-24 |
2024-10-15 |
Genedit Inc. |
Cationic polymer with alkyl side chains and use for biomolecule delivery
|
|
US11407995B1
(en)
|
2018-10-26 |
2022-08-09 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
EP3874037A4
(en)
|
2018-10-31 |
2021-12-15 |
Zymergen, Inc. |
DETERMINIST MULTIPLEXED SET OF DNA LIBRARIES
|
|
US11434477B1
(en)
|
2018-11-02 |
2022-09-06 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
|
US20230039976A1
(en)
|
2018-11-05 |
2023-02-09 |
Iovance Biotherapeutics, Inc. |
Selection of improved tumor reactive t-cells
|
|
US11739320B2
(en)
|
2018-11-05 |
2023-08-29 |
Wisconsin Alumni Research Foundation |
Gene correction of Pompe disease and other autosomal recessive disorders via RNA-guided nucleases
|
|
TW202039831A
(zh)
|
2018-11-05 |
2020-11-01 |
美商艾歐凡斯生物治療公司 |
對抗ｐｄ－１抗體呈現難治性之非小細胞肺癌（ｎｓｃｌｃ）病患之治療
|
|
TW202039830A
(zh)
|
2018-11-05 |
2020-11-01 |
美商艾歐凡斯生物治療公司 |
用於製造腫瘤浸潤性淋巴細胞之方法及其在免疫療法中之用途
|
|
CA3118493A1
(en)
|
2018-11-05 |
2020-05-14 |
Iovance Biotherapeutics, Inc. |
Expansion of tils utilizing akt pathway inhibitors
|
|
US12165743B2
(en)
|
2018-11-09 |
2024-12-10 |
The Broad Institute, Inc. |
Compressed sensing for screening and tissue imaging
|
|
CA3117730A1
(en)
|
2018-11-09 |
2020-05-14 |
Inari Agriculture, Inc. |
Rna-guided nucleases and dna binding proteins
|
|
US12402610B2
(en)
|
2018-11-09 |
2025-09-02 |
The Broad Institute, Inc. |
Methods and compositions for modulating innate lymphoid cell pathogenic effectors
|
|
US11166996B2
(en)
|
2018-12-12 |
2021-11-09 |
Flagship Pioneering Innovations V, Inc. |
Anellovirus compositions and methods of use
|
|
US12365888B2
(en)
|
2018-12-14 |
2025-07-22 |
Pioneer Hi-Bred International, Inc. |
CRISPR-Cas systems for genome editing
|
|
WO2020131586A2
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
US12264323B2
(en)
|
2018-12-17 |
2025-04-01 |
The Broad Institute, Inc. |
CRISPR CPF1 direct repeat variants
|
|
CA3124110A1
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Crispr-associated transposase systems and methods of use thereof
|
|
WO2020128478A1
(en)
|
2018-12-19 |
2020-06-25 |
King's College London |
Immunotherapeutic methods and compositions
|
|
JP7710372B2
(ja)
|
2018-12-19 |
2025-07-18 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
操作されたサイトカイン受容体対を使用して腫瘍浸潤リンパ球を拡大培養する方法及びその使用
|
|
ES2970169T3
(es)
*
|
2018-12-27 |
2024-05-27 |
Lifeedit Therapeutics Inc |
Polipéptidos útiles para edición génica y métodos de uso
|
|
EP3906415B1
(en)
|
2019-01-03 |
2026-04-15 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for enhancing cd8+ t cell-dependent immune responses in subjects suffering from cancer
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
WO2020160100A1
(en)
|
2019-01-29 |
2020-08-06 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
US11946040B2
(en)
|
2019-02-04 |
2024-04-02 |
The General Hospital Corporation |
Adenine DNA base editor variants with reduced off-target RNA editing
|
|
US12460230B2
(en)
|
2019-02-10 |
2025-11-04 |
The J. David Gladstone Institutes |
Modified mitochondrion and methods of use thereof
|
|
US10913941B2
(en)
|
2019-02-14 |
2021-02-09 |
Metagenomi Ip Technologies, Llc |
Enzymes with RuvC domains
|
|
US20220298494A1
(en)
*
|
2019-02-14 |
2022-09-22 |
Metagenomi Ip Technologies, Llc |
Enzymes with ruvc domains
|
|
AU2020223370B2
(en)
*
|
2019-02-14 |
2023-04-20 |
Metagenomi Therapeutics, Inc. |
Enzymes with RuvC domains
|
|
GB201902277D0
(en)
|
2019-02-19 |
2019-04-03 |
King S College London |
Therapeutic agents
|
|
US12208164B2
(en)
|
2019-02-28 |
2025-01-28 |
Unm Rainforest Innovations |
Modular metal-organic polyhedra superassembly compositions
|
|
US20220133795A1
(en)
|
2019-03-01 |
2022-05-05 |
Iovance Biotherapeutics, Inc. |
Expansion of Tumor Infiltrating Lymphocytes From Liquid Tumors and Therapeutic Uses Thereof
|
|
CA3130789A1
(en)
|
2019-03-07 |
2020-09-10 |
The Regents Of The University Of California |
Crispr-cas effector polypeptides and methods of use thereof
|
|
CN113728106A
(zh)
|
2019-03-08 |
2021-11-30 |
齐默尔根公司 |
微生物中的迭代基因组编辑
|
|
US11053515B2
(en)
|
2019-03-08 |
2021-07-06 |
Zymergen Inc. |
Pooled genome editing in microbes
|
|
KR20210149251A
(ko)
|
2019-03-08 |
2021-12-08 |
옵시디안 테라퓨틱스, 인크. |
조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법
|
|
US12534714B2
(en)
|
2019-03-18 |
2026-01-27 |
The Broad Institute, Inc. |
Type VII CRISPR proteins and systems
|
|
JP7657726B2
(ja)
|
2019-03-19 |
2025-04-07 |
ザ ブロード インスティテュート，インコーポレーテッド |
編集ヌクレオチド配列を編集するための方法および組成物
|
|
WO2020206036A1
(en)
|
2019-04-01 |
2020-10-08 |
The Broad Institute, Inc. |
Novel nucleic acid modifier
|
|
GB201905360D0
(en)
|
2019-04-16 |
2019-05-29 |
Univ Nottingham |
Fungal strains, production and uses thereof
|
|
US12473543B2
(en)
|
2019-04-17 |
2025-11-18 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
JP2022530224A
(ja)
|
2019-04-23 |
2022-06-28 |
ジーンエディット インコーポレイテッド |
アルキル側鎖を有するカチオン性ポリマー
|
|
US20220251152A1
(en)
|
2019-04-24 |
2022-08-11 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
PE20221123A1
(es)
|
2019-05-03 |
2022-07-13 |
Specific Biologics Inc |
Endonucleasa de escision dual encapsulada en lipidos para edicion de genes y adn
|
|
US11162079B2
(en)
|
2019-05-10 |
2021-11-02 |
The Regents Of The University Of California |
Blood type O Rh-hypo-immunogenic pluripotent cells
|
|
US20220243287A1
(en)
|
2019-05-13 |
2022-08-04 |
KWS SAAT SE & Co. KGaA |
Drought tolerance in corn
|
|
US20220249559A1
(en)
|
2019-05-13 |
2022-08-11 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
AU2020274996B2
(en)
|
2019-05-14 |
2024-02-01 |
Nuseed Nutritional Us Inc. |
Modified plants comprising a polynucleotide comprising a non-cognate promoter operably linked to a coding sequence that encodes a transcription factor
|
|
US20220235340A1
(en)
*
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
|
WO2020236972A2
(en)
|
2019-05-20 |
2020-11-26 |
The Broad Institute, Inc. |
Non-class i multi-component nucleic acid targeting systems
|
|
EP3973067A1
(en)
|
2019-05-21 |
2022-03-30 |
Sangamo Therapeutics, Inc. |
Controlled transgene expression in regulatory t cells
|
|
AR118995A1
(es)
|
2019-05-25 |
2021-11-17 |
Kws Saat Se & Co Kgaa |
Mejorador de la inducción de haploides
|
|
WO2020243370A1
(en)
|
2019-05-28 |
2020-12-03 |
Genedit Inc. |
Polymer comprising multiple functionalized sidechains for biomolecule delivery
|
|
BR112021021149A2
(pt)
|
2019-05-29 |
2021-12-14 |
Monsanto Technology Llc |
Métodos e composições para a geração de alelos dominantes utilizando a edição de genomas
|
|
US20220243178A1
(en)
|
2019-05-31 |
2022-08-04 |
The Broad Institute, Inc. |
Methods for treating metabolic disorders by targeting adcy5
|
|
WO2020244759A1
(en)
|
2019-06-05 |
2020-12-10 |
Klemm & Sohn Gmbh & Co. Kg |
New plants having a white foliage phenotype
|
|
WO2020254850A1
(en)
|
2019-06-21 |
2020-12-24 |
Vilmorin & Cie |
Improvement of quality and permanence of green color of peppers at maturity and over-maturity
|
|
MX2021014861A
(es)
|
2019-06-25 |
2022-06-22 |
Inari Agriculture Tech Inc |
Edicion genomica de reparacion dependiente de homologia mejorada.
|
|
JP2022539248A
(ja)
|
2019-07-02 |
2022-09-07 |
フレッド ハッチンソン キャンサー リサーチ センター |
組換えａｄ３５ベクター及び関連遺伝子治療改善
|
|
WO2021009299A1
(en)
|
2019-07-17 |
2021-01-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Bcl-xl:fkbp12 fusion proteins suitable for screening agents capable of slowing down the aging process
|
|
WO2021016043A1
(en)
|
2019-07-19 |
2021-01-28 |
Inari Agriculture, Inc. |
Improved homology dependent repair genome editing
|
|
WO2021019272A1
(en)
|
2019-07-31 |
2021-02-04 |
Vilmorin & Cie |
Tolerance to tolcndv in cucumber
|
|
US12371695B2
(en)
|
2019-08-02 |
2025-07-29 |
Monsanto Technology Llc |
Methods and compositions to promote targeted genome modifications using HUH endonucleases
|
|
WO2021026294A1
(en)
|
2019-08-06 |
2021-02-11 |
Children's Medical Center Corporation |
Methods and compositions for reconstituting microglia
|
|
EP3772542A1
(en)
|
2019-08-07 |
2021-02-10 |
KWS SAAT SE & Co. KGaA |
Modifying genetic variation in crops by modulating the pachytene checkpoint protein 2
|
|
JP2022543451A
(ja)
*
|
2019-08-08 |
2022-10-12 |
▲復▼旦大学 |
ＣＲＩＳＰＲ／Ｃａｓ９遺伝子編集システムおよびその適用
|
|
WO2021028359A1
(en)
|
2019-08-09 |
2021-02-18 |
Sangamo Therapeutics France |
Controlled expression of chimeric antigen receptors in t cells
|
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
WO2021046451A1
(en)
|
2019-09-06 |
2021-03-11 |
Obsidian Therapeutics, Inc. |
Compositions and methods for dhfr tunable protein regulation
|
|
EP4028514A1
(en)
*
|
2019-09-09 |
2022-07-20 |
Beam Therapeutics Inc. |
Novel crispr enzymes, methods, systems and uses thereof
|
|
CN115175996A
(zh)
|
2019-09-20 |
2022-10-11 |
博德研究所 |
新颖vi型crispr酶和系统
|
|
CN114729376A
(zh)
|
2019-09-23 |
2022-07-08 |
欧米茄治疗公司 |
用于调节肝细胞核因子4α(HNF4α)基因表达的组合物和方法
|
|
AU2020355000A1
(en)
|
2019-09-23 |
2022-03-17 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating apolipoprotein B (APOB) gene expression
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
EP3808766A1
(en)
|
2019-10-15 |
2021-04-21 |
Sangamo Therapeutics France |
Chimeric antigen receptor specific for interleukin-23 receptor
|
|
AU2020368539A1
(en)
|
2019-10-16 |
2022-04-28 |
Massachusetts Institute Of Technology |
Engineered muscle targeting compositions
|
|
US20230357788A1
(en)
|
2019-10-17 |
2023-11-09 |
KWS SAAT SE & Co. KGaA |
Enhanced disease resistance of crops by downregulation of repressor genes
|
|
JP2022553389A
(ja)
|
2019-10-25 |
2022-12-22 |
アイオバンス バイオセラピューティクス，インコーポレイテッド |
腫瘍浸潤リンパ球の遺伝子編集及び免疫療法におけるその使用
|
|
US12521451B2
(en)
|
2019-11-08 |
2026-01-13 |
Regeneron Pharmaceuticals, Inc. |
CRISPR and AAV strategies for x-linked juvenile retinoschisis therapy
|
|
BR112022009137A2
(pt)
*
|
2019-11-13 |
2022-07-26 |
Crispr Therapeutics Ag |
Métodos de fabricação de células t com receptor de antígeno quimérico (car)
|
|
TW202132333A
(zh)
*
|
2019-11-13 |
2021-09-01 |
瑞士商Ｃｒｉｓｐｒ治療公司 |
製造可表達嵌合抗原受體的ｔ細胞製法
|
|
EP4057802A1
(en)
|
2019-11-14 |
2022-09-21 |
Vilmorin & Cie |
Resistance to acidovorax valerianellae in corn salad
|
|
WO2021102084A1
(en)
|
2019-11-22 |
2021-05-27 |
President And Fellows Of Harvard College |
Ionic liquids for drug delivery
|
|
WO2021113270A1
(en)
|
2019-12-02 |
2021-06-10 |
Shape Therapeutics Inc. |
Therapeutic editing
|
|
US12516291B2
(en)
|
2019-12-11 |
2026-01-06 |
Iovance Biotherapeutics, Inc. |
Processes for the production of tumor infiltrating lymphocytes (TILs) and methods of using the same
|
|
US20230020092A1
(en)
|
2019-12-19 |
2023-01-19 |
Entrada Therapeutics, Inc. |
Compositions for delivery of antisense compounds
|
|
IL271656A
(en)
|
2019-12-22 |
2021-06-30 |
Yeda Res & Dev |
System and methods for identifying cells that have undergone genome editing
|
|
AU2021207810A1
(en)
|
2020-01-13 |
2022-08-04 |
Sana Biotechnology, Inc. |
Modification of blood type antigens
|
|
AU2021211713A1
(en)
|
2020-01-23 |
2022-08-25 |
The Children's Medical Center Corporation |
Stroma-free T cell differentiation from human pluripotent stem cells
|
|
WO2021151085A2
(en)
|
2020-01-24 |
2021-07-29 |
The General Hospital Corporation |
Crispr-cas enzymes with enhanced on-target activity
|
|
EP4093864A4
(en)
|
2020-01-24 |
2024-04-10 |
The General Hospital Corporation |
Unconstrained genome targeting with near-pamless engineered crispr-cas9 variants
|
|
CA3167275A1
(en)
|
2020-01-29 |
2021-08-05 |
Foghorn Therapeutics Inc. |
Compounds and uses thereof
|
|
EP3872190A1
(en)
|
2020-02-26 |
2021-09-01 |
Antibodies-Online GmbH |
A method of using cut&run or cut&tag to validate crispr-cas targeting
|
|
CA3174483A1
(en)
|
2020-03-04 |
2021-09-10 |
Flagship Pioneering Innovations Vi, Llc |
Improved methods and compositions for modulating a genome
|
|
CN116096886A
(zh)
|
2020-03-11 |
2023-05-09 |
欧米茄治疗公司 |
用于调节叉头框p3(foxp3)基因表达的组合物和方法
|
|
CA3172120A1
(en)
|
2020-03-20 |
2021-09-23 |
Inserm (Institut De La Sante Et De La Recherche Medicale) |
Chimeric antigen receptor specific for human cd45rc and uses thereof
|
|
GB2608292B
(en)
|
2020-03-31 |
2024-02-14 |
Metagenomi Inc |
Class II, type II CRISPR systems
|
|
WO2021202938A1
(en)
|
2020-04-03 |
2021-10-07 |
Creyon Bio, Inc. |
Oligonucleotide-based machine learning
|
|
US11433121B1
(en)
|
2020-04-03 |
2022-09-06 |
National Technology & Engineering Solutions Of Sandia, Llc |
Lipid composition for the delivery of therapeutic cargos
|
|
WO2021216622A1
(en)
|
2020-04-21 |
2021-10-28 |
Aspen Neuroscience, Inc. |
Gene editing of gba1 in stem cells and method of use of cells differentiated therefrom
|
|
WO2021216623A1
(en)
|
2020-04-21 |
2021-10-28 |
Aspen Neuroscience, Inc. |
Gene editing of lrrk2 in stem cells and method of use of cells differentiated therefrom
|
|
US20230151343A1
(en)
*
|
2020-04-24 |
2023-05-18 |
Institute For Basic Science |
Genome editing using cas9 or cas9 variant
|
|
EP4146794A1
(en)
|
2020-05-04 |
2023-03-15 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
EP4146797A1
(en)
|
2020-05-06 |
2023-03-15 |
Orchard Therapeutics (Europe) Limited |
Treatment for neurodegenerative diseases
|
|
DE112021002672T5
(de)
|
2020-05-08 |
2023-04-13 |
President And Fellows Of Harvard College |
Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
|
|
US12383555B2
(en)
|
2020-05-20 |
2025-08-12 |
Foghorn Therapeutics Inc. |
Methods of treating cancers
|
|
AU2021275995B2
(en)
|
2020-05-22 |
2026-02-12 |
Insitro, Inc. |
Predicting disease outcomes using machine learned models
|
|
PE20230080A1
(es)
|
2020-05-29 |
2023-01-11 |
Kws Saat Se And Co Kgaa |
Induccion de haploides en plantas
|
|
WO2021245435A1
(en)
|
2020-06-03 |
2021-12-09 |
Vilmorin & Cie |
Melon plants resistant to scab disease, aphids and powdery mildew
|
|
CA3186284A1
(en)
|
2020-06-05 |
2021-12-09 |
Vilmorin & Cie |
Resistance in plants of solanum lycopersicum to the tobrfv
|
|
CA3185455A1
(en)
|
2020-06-11 |
2021-12-16 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
|
WO2022029080A1
(en)
|
2020-08-03 |
2022-02-10 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy
|
|
WO2022034474A1
(en)
|
2020-08-10 |
2022-02-17 |
Novartis Ag |
Treatments for retinal degenerative diseases
|
|
AU2021328478A1
(en)
|
2020-08-20 |
2023-04-20 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating egfr positive cancers
|
|
WO2022040454A1
(en)
|
2020-08-20 |
2022-02-24 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating mesothelin positive cancers
|
|
KR102859550B1
(ko)
|
2020-08-20 |
2025-09-16 |
에이투 바이오쎄라퓨틱스, 인크. |
Ceacam 양성 암을 치료하기 위한 조성물 및 방법
|
|
MA63547B1
(fr)
|
2020-10-02 |
2025-08-29 |
Vilmorin & Cie |
Melon à durée de conservation prolongée
|
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
US20230372397A1
(en)
|
2020-10-06 |
2023-11-23 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
US20230147779A1
(en)
|
2020-10-28 |
2023-05-11 |
GeneEdit, Inc. |
Polymer with cationic and hydrophobic side chains
|
|
EP4243608A1
(en)
|
2020-11-11 |
2023-09-20 |
Leibniz-Institut für Pflanzenbiochemie (IPB) |
Fusion protein for editing endogenous dna of a eukaryotic cell
|
|
KR20230107617A
(ko)
|
2020-11-13 |
2023-07-17 |
노파르티스 아게 |
키메라 항원 수용체(car)-발현 세포를 사용한 병용 요법
|
|
EP4001429A1
(en)
|
2020-11-16 |
2022-05-25 |
Antibodies-Online GmbH |
Analysis of crispr-cas binding and cleavage sites followed by high-throughput sequencing (abc-seq)
|
|
IL303102A
(en)
|
2020-12-03 |
2023-07-01 |
Vilmorin & Cie |
Tomato plants resistant to TOMMV, TOMV, TMV, TOBRFV and suitable resistant genes
|
|
CA3202483A1
(en)
|
2020-12-17 |
2022-06-23 |
Maria Fardis |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
|
US20240123067A1
(en)
|
2020-12-17 |
2024-04-18 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocyte therapies
|
|
EP4267157A4
(en)
|
2020-12-23 |
2025-05-07 |
Flagship Pioneering Innovations V, Inc. |
IN VITRO ASSEMBLY OF ANELLOVIRUS CAPSIDS WITH RNA
|
|
TW202241508A
(zh)
|
2021-01-29 |
2022-11-01 |
美商艾歐凡斯生物治療公司 |
細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
|
|
IL304857A
(en)
|
2021-02-16 |
2023-10-01 |
A2 Biotherapeutics Inc |
Preparations and methods for treating HER2 POSITIVE cancer
|
|
GB202103131D0
(en)
|
2021-03-05 |
2021-04-21 |
Biosystems Tech Limited |
Method for preparation of research organisms
|
|
JP2024509268A
(ja)
|
2021-03-09 |
2024-02-29 |
フォグホーン セラピューティクス インコーポレイテッド |
結晶形、それらを含有する組成物、及びそれらの使用方法
|
|
WO2022198141A1
(en)
|
2021-03-19 |
2022-09-22 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd69 selection and gene knockout in tils
|
|
AU2022246174A1
(en)
|
2021-03-25 |
2023-09-14 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for t-cell coculture potency assays and use with cell therapy products
|
|
US20250243244A1
(en)
|
2021-03-31 |
2025-07-31 |
Entrada Therapeutics, Inc. |
Cyclic cell penetrating peptides
|
|
WO2022208489A1
(en)
|
2021-04-02 |
2022-10-06 |
Vilmorin & Cie |
Semi-determinate or determinate growth habit trait in cucurbita
|
|
EP4326287A2
(en)
|
2021-04-19 |
2024-02-28 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
WO2022232638A2
(en)
*
|
2021-04-30 |
2022-11-03 |
Metagenomi, Inc. |
Enzymes with ruvc domains
|
|
US20240374761A1
(en)
|
2021-05-05 |
2024-11-14 |
Radius Pharmaceuticals, Inc. |
Animal model having homologous recombination of mouse pth1 receptor
|
|
WO2022240760A2
(en)
|
2021-05-10 |
2022-11-17 |
Entrada Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR MODULATING mRNA SPLICING
|
|
US20240358845A1
(en)
|
2021-05-10 |
2024-10-31 |
Entrada Therapeutics, Inc. |
Compositions and methods for intracellular therapeutics
|
|
WO2022240721A1
(en)
|
2021-05-10 |
2022-11-17 |
Entrada Therapeutics, Inc. |
Compositions and methods for modulating interferon regulatory factor-5 (irf-5) activity
|
|
WO2022245754A1
(en)
|
2021-05-17 |
2022-11-24 |
Iovance Biotherapeutics, Inc. |
Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
IL308806A
(en)
|
2021-06-01 |
2024-01-01 |
Arbor Biotechnologies Inc |
Gene editing systems including nuclease crisper and their uses
|
|
WO2022261561A1
(en)
|
2021-06-11 |
2022-12-15 |
Genedit Inc. |
Biodegradable polymer comprising side chains with polyamine and polyalkylene oxide groups
|
|
PE20242357A1
(es)
|
2021-06-23 |
2024-12-16 |
Entrada Therapeutics Inc |
Compuestos antisentido y metodos para dirigirse a repeticiones cug
|
|
US20240327859A1
(en)
*
|
2021-07-02 |
2024-10-03 |
University Of Maryland, College Park |
Cytidine deaminases and methods of genome editing using the same
|
|
EP4367242A2
(en)
|
2021-07-07 |
2024-05-15 |
Omega Therapeutics, Inc. |
Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression
|
|
US20240365776A1
(en)
|
2021-07-22 |
2024-11-07 |
Iovance Biotherapeutics, Inc |
Method for cryopreservation of solid tumor fragments
|
|
US20240342285A1
(en)
|
2021-07-28 |
2024-10-17 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
|
AR126622A1
(es)
|
2021-07-30 |
2023-10-25 |
Kws Saat Se & Co Kgaa |
Plantas con digestibilidad mejorada y haplotipos marcadores
|
|
US20250280784A1
(en)
|
2021-08-06 |
2025-09-11 |
Vilmorin & Cie |
Resistance to leveillula taurica in pepper
|
|
CA3225082A1
(en)
|
2021-08-27 |
2023-03-02 |
Brian C. Thomas |
Enzymes with ruvc domains
|
|
US20240368619A1
(en)
|
2021-09-02 |
2024-11-07 |
SESVanderHave NV |
Methods and compositions for ppo herbicide tolerance
|
|
JP7125727B1
(ja)
|
2021-09-07 |
2022-08-25 |
国立大学法人千葉大学 |
核酸配列改変用組成物および核酸配列の標的部位を改変する方法
|
|
JP2024533311A
(ja)
*
|
2021-09-08 |
2024-09-12 |
フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー |
ゲノムを調節するための方法及び組成物
|
|
JP2024534945A
(ja)
|
2021-09-10 |
2024-09-26 |
アジレント・テクノロジーズ・インク |
化学修飾を有するプライム編集のためのガイドｒｎａ
|
|
KR20240099180A
(ko)
|
2021-09-20 |
2024-06-28 |
레비비코르 인코포레이션 |
이종이식을 위한 10개의 유전자 변형을 포함하는 다중전이유전자 돼지
|
|
WO2023056291A1
(en)
|
2021-09-28 |
2023-04-06 |
Acrigen Biosciences |
Compositions and methods for nucleic acid modifications
|
|
WO2023052508A2
(en)
|
2021-09-30 |
2023-04-06 |
Astrazeneca Ab |
Use of inhibitors to increase efficiency of crispr/cas insertions
|
|
WO2023060132A1
(en)
*
|
2021-10-05 |
2023-04-13 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Allele specific editing to treat fus-induced neurodegeneration
|
|
CN118382429A
(zh)
|
2021-10-08 |
2024-07-23 |
哈佛大学校长及研究员协会 |
用于药物递送的离子液体
|
|
WO2023077015A2
(en)
|
2021-10-27 |
2023-05-04 |
Iovance Biotherapeutics, Inc. |
Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
|
|
KR20240099393A
(ko)
|
2021-11-01 |
2024-06-28 |
톰 바이오사이언시스, 인코포레이티드 |
유전자 편집 기구와 핵산 카고의 동시 전달을 위한 단일 작제물 플랫폼
|
|
EP4426832A1
(en)
|
2021-11-03 |
2024-09-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Precise genome editing using retrons
|
|
EP4430167A1
(en)
|
2021-11-10 |
2024-09-18 |
Iovance Biotherapeutics, Inc. |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
|
WO2023085433A1
(ja)
|
2021-11-15 |
2023-05-19 |
国立大学法人鳥取大学 |
ヒト細胞内でヒト人工染色体ベクターを作製する方法
|
|
MX2024006257A
(es)
|
2021-11-24 |
2024-07-29 |
Metagenomi Inc |
Sistemas de endonucleasas.
|
|
EP4437092A1
(en)
|
2021-11-26 |
2024-10-02 |
Epigenic Therapeutics Inc. |
Method of modulating pcsk9 and uses thereof
|
|
GB202118058D0
(en)
|
2021-12-14 |
2022-01-26 |
Univ Warwick |
Methods to increase yields in crops
|
|
US20230279442A1
(en)
|
2021-12-15 |
2023-09-07 |
Versitech Limited |
Engineered cas9-nucleases and method of use thereof
|
|
US20250059239A1
(en)
|
2021-12-17 |
2025-02-20 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae fusion glycoproteins
|
|
EP4448775A1
(en)
|
2021-12-17 |
2024-10-23 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
|
WO2023122764A1
(en)
|
2021-12-22 |
2023-06-29 |
Tome Biosciences, Inc. |
Co-delivery of a gene editor construct and a donor template
|
|
MX2024007908A
(es)
|
2021-12-23 |
2024-09-10 |
Univ Massachusetts |
Tratamiento terapeutico para trastorno asociado con x fragil.
|
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
WO2023147488A1
(en)
|
2022-01-28 |
2023-08-03 |
Iovance Biotherapeutics, Inc. |
Cytokine associated tumor infiltrating lymphocytes compositions and methods
|
|
EP4472646A1
(en)
|
2022-02-01 |
2024-12-11 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
US20250144235A1
(en)
|
2022-02-02 |
2025-05-08 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
US20250099584A1
(en)
|
2022-02-18 |
2025-03-27 |
Institut National de la Santé et de la Recherche Médicale |
Use of tcr-deficient car-tregs in combination with anti-tcr complex monoclonal antibodies for inducing durable tolerance
|
|
EP4504220A1
(en)
|
2022-04-06 |
2025-02-12 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
EP4256950A1
(en)
|
2022-04-06 |
2023-10-11 |
Vilmorin et Cie |
Tolerance to cgmmv in cucumber
|
|
CA3248034A1
(en)
|
2022-04-15 |
2023-10-19 |
Iovance Biotherapeutics, Inc. |
METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT
|
|
WO2023205744A1
(en)
|
2022-04-20 |
2023-10-26 |
Tome Biosciences, Inc. |
Programmable gene insertion compositions
|
|
WO2023215831A1
(en)
|
2022-05-04 |
2023-11-09 |
Tome Biosciences, Inc. |
Guide rna compositions for programmable gene insertion
|
|
EP4522210A1
(en)
|
2022-05-09 |
2025-03-19 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified genome for gene therapy
|
|
WO2023220040A1
(en)
|
2022-05-09 |
2023-11-16 |
Synteny Therapeutics, Inc. |
Erythroparvovirus with a modified capsid for gene therapy
|
|
EP4522221A1
(en)
|
2022-05-09 |
2025-03-19 |
Entrada Therapeutics, Inc. |
Compositions and methods for delivery of nucleic acid therapeutics
|
|
EP4522201A1
(en)
|
2022-05-09 |
2025-03-19 |
Synteny Therapeutics, Inc. |
Erythroparvovirus compositions and methods for gene therapy
|
|
EP4522202A1
(en)
|
2022-05-10 |
2025-03-19 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with an il-15r agonist
|
|
WO2023225670A2
(en)
|
2022-05-20 |
2023-11-23 |
Tome Biosciences, Inc. |
Ex vivo programmable gene insertion
|
|
EP4641202A3
(en)
|
2022-05-25 |
2026-01-21 |
Flagship Pioneering Innovations VII, LLC |
Compositions and methods for modulation of immune responses
|
|
US20250319115A1
(en)
|
2022-05-25 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and Methods for Modulating Cytokines
|
|
US20250320254A1
(en)
|
2022-05-25 |
2025-10-16 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and Methods for Modulating Circulating Factors
|
|
JP2025517969A
(ja)
|
2022-05-25 |
2025-06-12 |
フラッグシップ パイオニアリング イノベーションズ セブン，エルエルシー |
腫瘍抑制因子及び癌遺伝子の調節のための組成物及び方法
|
|
CA3253328A1
(en)
|
2022-05-25 |
2023-11-30 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and Modulation Methods of Genetic Drivers
|
|
EP4299739A1
(en)
|
2022-06-30 |
2024-01-03 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
|
EP4299733A1
(en)
|
2022-06-30 |
2024-01-03 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
|
WO2024005864A1
(en)
|
2022-06-30 |
2024-01-04 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
|
GB2621813A
(en)
|
2022-06-30 |
2024-02-28 |
Univ Newcastle |
Preventing disease recurrence in Mitochondrial replacement therapy
|
|
WO2024005863A1
(en)
|
2022-06-30 |
2024-01-04 |
Inari Agriculture Technology, Inc. |
Compositions, systems, and methods for genome editing
|
|
JP2025525569A
(ja)
|
2022-07-18 |
2025-08-05 |
レナゲード セラピューティクス マネージメント インコーポレイテッド |
遺伝子編集成分、システム、及び使用方法
|
|
WO2024020587A2
(en)
|
2022-07-22 |
2024-01-25 |
Tome Biosciences, Inc. |
Pleiopluripotent stem cell programmable gene insertion
|
|
WO2024023734A1
(en)
|
2022-07-26 |
2024-02-01 |
Bit Bio Limited |
MULTI-gRNA GENOME EDITING
|
|
WO2024030930A2
(en)
*
|
2022-08-01 |
2024-02-08 |
The Johns Hopkins University |
Compositions and methods for modifying muller glial cells
|
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
|
US20260055146A1
(en)
|
2022-08-24 |
2026-02-26 |
Sana Biotechnology, Inc. |
Delivery of heterologous proteins
|
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
US20250386788A1
(en)
|
2022-08-26 |
2025-12-25 |
KWS SAAT SE & Co. KGaA |
Use of paired genes in hybrid breeding
|
|
WO2024047587A1
(en)
|
2022-08-31 |
2024-03-07 |
Regel Therapeutics, Inc. |
Cas-phi compositions and methods of use
|
|
WO2024047605A1
(en)
|
2022-09-01 |
2024-03-07 |
SESVanderHave NV |
Methods and compositions for ppo herbicide tolerance
|
|
WO2024050544A2
(en)
|
2022-09-01 |
2024-03-07 |
J.R. Simplot Company |
Enhanced targeted knock-in frequency in host genomes through crispr exonuclease processing
|
|
WO2024052318A1
(en)
|
2022-09-06 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Novel dual split car-t cells for the treatment of cd38-positive hematological malignancies
|
|
US20260098062A1
(en)
|
2022-09-21 |
2026-04-09 |
Sana Biotechnology, Inc. |
Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
|
|
WO2024074888A2
(en)
|
2022-10-03 |
2024-04-11 |
The Regents Of The University Of California |
Circumventing barriers to hybrid crops from genetically distant crosses
|
|
WO2024081820A1
(en)
|
2022-10-13 |
2024-04-18 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
|
WO2024098027A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Methods for tumor infiltrating lymphocyte (til) expansion related to cd39/cd103 selection
|
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
EP4615424A1
(en)
|
2022-11-10 |
2025-09-17 |
Sail Biomedicines, Inc. |
Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs
|
|
EP4623072A2
(en)
|
2022-11-21 |
2025-10-01 |
Iovance Biotherapeutics, Inc. |
Two-dimensional processes for the expansion of tumor infiltrating lymphocytes and therapies therefrom
|
|
WO2024118836A1
(en)
|
2022-11-30 |
2024-06-06 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes with shortened rep step
|
|
WO2024119157A1
(en)
|
2022-12-02 |
2024-06-06 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|
|
WO2024138194A1
(en)
|
2022-12-22 |
2024-06-27 |
Tome Biosciences, Inc. |
Platforms, compositions, and methods for in vivo programmable gene insertion
|
|
IL321652A
(en)
|
2022-12-29 |
2025-08-01 |
Vilmorin & Cie |
Tomato plants resistant to TSWV-resistant varieties and genes suitable for resistance
|
|
EP4658061A1
(en)
|
2023-02-01 |
2025-12-10 |
United Beet Seeds |
Beet yellows virus resistance
|
|
WO2024168265A1
(en)
|
2023-02-10 |
2024-08-15 |
Possible Medicines Llc |
Aav delivery of rna guided recombination system
|
|
WO2024168253A1
(en)
|
2023-02-10 |
2024-08-15 |
Possible Medicines Llc |
Delivery of an rna guided recombination system
|
|
WO2024173645A1
(en)
|
2023-02-15 |
2024-08-22 |
Arbor Biotechnologies, Inc. |
Gene editing method for inhibiting aberrant splicing in stathmin 2 (stmn2) transcript
|
|
US12383615B2
(en)
|
2023-03-23 |
2025-08-12 |
Carbon Biosciences, Inc. |
Protoparvovirus compositions comprising a protoparvovirus variant VP1 capsid polypeptide and related methods
|
|
US12239091B2
(en)
|
2023-03-27 |
2025-03-04 |
Redsea Science And Technology Inc. |
Tomato plant designated ‘MX20-06’
|
|
CN121127605A
(zh)
|
2023-03-29 |
2025-12-12 |
阿斯利康(瑞典)有限公司 |
使用抑制剂来提高CRISPR/Cas插入的效率
|
|
WO2024211287A1
(en)
|
2023-04-03 |
2024-10-10 |
Seagen Inc. |
Production cell lines with targeted integration sites
|
|
EP4698665A1
(en)
|
2023-04-18 |
2026-02-25 |
Sana Biotechnology, Inc. |
Engineered protein g fusogens and related lipid particles and methods thereof
|
|
WO2024220598A2
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Lentiviral vectors with two or more genomes
|
|
EP4698666A1
(en)
|
2023-04-18 |
2026-02-25 |
Sana Biotechnology, Inc. |
Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
|
|
US20240352485A1
(en)
|
2023-04-19 |
2024-10-24 |
Flagship Pioneering Innovations Vii, Llc |
Compositions and methods for the production of libraries
|
|
CN121443140A
(zh)
|
2023-04-21 |
2026-01-30 |
非营利性组织佛兰芒综合大学生物技术研究所 |
用于作物产量提升的等位基因组合
|
|
EP4701406A1
(en)
|
2023-04-28 |
2026-03-04 |
Vilmorin & Cie |
Genetic determinants conferring improved tobrfv resistance
|
|
WO2024234006A1
(en)
|
2023-05-11 |
2024-11-14 |
Tome Biosciences, Inc. |
Systems, compositions, and methods for targeting liver sinusodial endothelial cells (lsecs)
|
|
IL324634A
(en)
|
2023-05-15 |
2026-01-01 |
Nchroma Bio Inc |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
WO2024236547A1
(en)
|
2023-05-18 |
2024-11-21 |
Inceptor Bio, Llc |
Modified phagocytic cells expressing chimeric antigen receptors comprising a herpes virus entry mediator (hvem) co-stimulatory domain and uses thereof
|
|
KR20260016952A
(ko)
|
2023-05-23 |
2026-02-04 |
사나 바이오테크놀로지, 인크. |
탠덤 퓨소젠 및 관련 지질 입자
|
|
WO2024243438A2
(en)
|
2023-05-23 |
2024-11-28 |
Omega Therapeutics, Inc. |
Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression
|
|
WO2025006419A1
(en)
|
2023-06-26 |
2025-01-02 |
Flagship Pioneering Innovations Vii, Llc |
Engineered plasmodia and related methods
|
|
WO2025003305A1
(en)
|
2023-06-28 |
2025-01-02 |
Vilmorin & Cie |
Pepper resistance to meloidogyne enterolobii
|
|
WO2025021893A1
(en)
|
2023-07-24 |
2025-01-30 |
Vilmorin & Cie |
Resistance to cysdv in melons
|
|
US20250043304A1
(en)
|
2023-08-03 |
2025-02-06 |
J.R. Simplot Company |
Fusarium wilt resistance genes
|
|
WO2025046513A1
(en)
|
2023-08-29 |
2025-03-06 |
Inceptor Bio, Llc |
Methods of manufacturing myeloid-derived cells from hematopoietic stem cells and compositions and uses thereof
|
|
WO2025050069A1
(en)
|
2023-09-01 |
2025-03-06 |
Tome Biosciences, Inc. |
Programmable gene insertion using engineered integration enzymes
|
|
AU2024335327A1
(en)
|
2023-09-01 |
2026-03-26 |
Renagade Therapeutics Management Inc. |
Gene editing systems, compositions, and methods for treatment of vexas syndrome
|
|
WO2025054202A1
(en)
|
2023-09-05 |
2025-03-13 |
Sana Biotechnology, Inc. |
Method of screening a sample comprising a transgene with a unique barcode
|
|
WO2025054540A1
(en)
|
2023-09-08 |
2025-03-13 |
Iovance Biotherapeutics, Inc. |
Methods of gene-editing using programmable nucleases
|
|
WO2025059215A1
(en)
|
2023-09-12 |
2025-03-20 |
Aadigen, Llc |
Methods and compositions for treating or preventing cancer
|
|
WO2025064408A1
(en)
|
2023-09-18 |
2025-03-27 |
The Broad Institute, Inc. |
Compositions and methods for treating cardiovascular disease
|
|
GB202314578D0
(en)
|
2023-09-22 |
2023-11-08 |
Univ Manchester |
Methods of producing homoplasmic modified plants or parts thereof
|
|
WO2025076141A1
(en)
|
2023-10-03 |
2025-04-10 |
Inari Agriculture Technology, Inc. |
Viral delivery of grna to the scion
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025101484A1
(en)
|
2023-11-06 |
2025-05-15 |
Iovance Biotherapeutics, Inc. |
Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
|
|
US20250161347A1
(en)
|
2023-11-22 |
2025-05-22 |
Flagship Pioneering Innovations Vii, Llc |
Methods and compositions for treating non-alcoholic fatty liver disease
|
|
WO2025151838A1
(en)
|
2024-01-12 |
2025-07-17 |
Sana Biotechnology, Inc. |
Safety switches to control in vitro and in vivo proliferation of cell therapy products
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
WO2025168705A1
(en)
|
2024-02-08 |
2025-08-14 |
Vib Vzw |
Means and methods for the production of saponins with endosomal escape-enhancing properties
|
|
WO2025171210A1
(en)
|
2024-02-09 |
2025-08-14 |
Arbor Biotechnologies, Inc. |
Compositions and methods for gene editing via homology-mediated end joining
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025184529A1
(en)
|
2024-03-01 |
2025-09-04 |
Sana Biotechnology, Inc. |
Viral particles with fusogen display and related compositions and methods
|
|
WO2025186284A1
(en)
|
2024-03-05 |
2025-09-12 |
Vilmorin & Cie |
Increased yield in cucumber
|
|
WO2025194019A1
(en)
|
2024-03-14 |
2025-09-18 |
Flagship Pioneering Innovations Vii, Llc |
Methods for treating liver fibrosis and non-alcoholic fatty liver disease
|
|
EP4677108A1
(en)
|
2024-04-22 |
2026-01-14 |
Basecamp Research Ltd |
Method and compositions for detecting off-target editing
|
|
WO2025224182A2
(en)
|
2024-04-23 |
2025-10-30 |
Basecamp Research Ltd |
Single construct platform for simultaneous delivery of gene editing machinery and nucleic acid cargo
|
|
WO2025240947A1
(en)
|
2024-05-17 |
2025-11-20 |
University Of Massachusetts |
Therapeutic treatment for fragile x-associated disorder
|
|
WO2025245188A2
(en)
|
2024-05-21 |
2025-11-27 |
Flagship Pioneering Innovations Vii, Llc |
Methods of treating liver steatosis and non-alcoholic fatty liver disease
|
|
WO2025259554A1
(en)
|
2024-06-13 |
2025-12-18 |
J.R. Simplot Company |
Engineering remontant flowering in rosaceae
|
|
WO2026006542A2
(en)
|
2024-06-26 |
2026-01-02 |
Yale University |
Compositions and methods for crispr/cas9 based reactivation of human angelman syndrome
|
|
WO2026015829A2
(en)
|
2024-07-12 |
2026-01-15 |
Arbor Biotechnologies, Inc. |
Small reverse transcriptases and gene editing systems comprising such
|
|
WO2026015832A2
(en)
|
2024-07-12 |
2026-01-15 |
Arbor Biotechnologies, Inc. |
Reverse transcriptases and gene editing systems comprising such
|
|
WO2026017833A1
(en)
|
2024-07-17 |
2026-01-22 |
Vilmorin & Cie |
Tswv-resistant pepper
|
|
US20260043035A1
(en)
|
2024-08-08 |
2026-02-12 |
Invaio Sciences, Inc. |
Nature-derived lipid particles for use in agriculture
|
|
WO2026047626A1
(en)
|
2024-08-30 |
2026-03-05 |
Inceptor Bio, Llc |
Compositions and methods involving immune cells engineered for binding bispecific antibodies for use in cell therapy
|